

AUTHOR INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number.

Page references to Supplement 1 (July 2003), Supplement 2 (July 2003), Supplement 3 (October 2003), Supplement 4 (November 2003), and Supplement 5 (December 2003) are preceded, respectively, by S1:, S2:, S3:, S4:, and S5:.

Abbott, K.C., 1058
Abe, K., 76
Abraham, M., 797
Abramson, F., 561
Abul-Ezz, S.R., 202
Adachi, M., 1287
Adler, S.G., 395
Agodoa, L.Y., 1058
Aguilera, A., 787
Ahuja, T.S., 376
Akiba, T., 303
Akioka, Y., 1121
Alhejaili, F., S1:24
Al-Hilali, N., 797
Allen, A.S., 1260
Allon, M., 388, 612
Al Mousawi, M., 797
Al-Muzeirei, I.A., 797
Alpers, C.E., 605
Al-Shamari, A., 591
Amadori, F., 3:E11
Ambühl, P.M., 193
Ammann, P., 193
Anderson, P.W., 456
André, J.-L., 5:E19
Andreoni, K., 5:E23
Anger, M.S., 315
Ankenbrandt, M., 926
Antignac, C., 1:E2
Appel, L.J., 256
Arakawa, H., 271
Araki, S.-i., 943
Arcidiacono, T., 1177
Arnold, R.M., 813
Ars, E., 952
Ascher, N.L., 362
Ashizawa, M., 76
Asif, A., 229, 1270, 1293
Avram, M.M., 864
Ayanian, J.Z., 1043
Azzi, A., 821
Badalamenti, S., 143
Badenas, C., 952
Bae, K., 2:E7
Baek, H.W., 6:E26
Bagga, A., 1114
Baggio, E., 331
Baines, L.S., 431
Bajo, M.A., 787
Bakris, G.L., 617, 1301
Balducci, A., 1036
Baliga, S., 532
Ballanti, P., 1036
Bankhurst, A., 1212
Barone, G.W., 202
Barré, P.E., 693
Bartlett, C., 551
Barz, A., 752
Baumgarten, D.A., 601
Beck, G.J., 44
Becker, B., 62
Becker, D.J., 117
Bedogni, V., 331
Bendel, K.J., 3:xlviii
Bennett, W.M., 217
Benoit, M.O., 513
Bergstrahl, E.J., 685
Berns, J.S., 325
Berto, I.M., 67
Bhattacharia, K.F., 3:E17
Bianchin, C., 1177
Bihorac, A., 704
Binik, Y.M., 693
Blagg, C.R., S1:1
Blake, P.G., S1:42
Bleyer, A.J., 2:E8
Blinder, J., 1:lxix
Block, G., 864
Block, S.D., 813
Boczuła, M., 539
Boero, R., 67
Bonucci, E., 1036
Bosnyak, Z., 117
Bourgoignie, J.J., 1270, 1293
Bowden, D.W., 133
Brabant, G., 62
Brancaccio, D., 143
Brancati, F.L., 249, 256
Brayman, K., 1000
Bredi, E., 143
Brémont-Gignac, D., 5:E19
Brewster, P.S., 926
Briançon, S., 474
Brophy, P.D., 1248
Brown, W.W., 22
Buisson, C., 513
Bulucu, F., 1164
Bunchman, T.E., 1248
Burding, J.E., 234
Burket, M.W., 926
Burkhart, J., 1082
Burnett, S., 1184
Burns, A., 582
Burns, J.E., 1000
Byers, P., 229, 1270
Cai, W., 532
Calabria, S., 1036
Calonge, V.M., 513
Campbell, D.A. Jr., 151
Campbell, H., 3:E15
Carmody, S.S., 813
Carpenter, B., 1107
Carrie, B.J., 1020
Cass, A., 1043
Castro, M.J., 787
Catalano, C., 722
Catania, A., 143
Cattran, D.C., 846
Cauci, F., 3:E11
Cavallone, D., 658
Cecka, J.M., 882
Celadilla, O., 787
Cernelc, P., 746
Cetin, T., 1164
Chalermkulrat, W., 1149
Chan, L.Y.Y., 173
Chan, T.M., 173
Chang, C.-F., 3:E14
Chapman, A.B., 1305
Charbonneau, P., 497
Charest, A.F., 1193
Charney, D.A., 1097
Chen, C.-H., 990
Chen, J.-Y., 3:E14
Chen, M.L.W., 623
Chen, S.-C., 22
Chen, W.-T., 158
Chen, Y.-C., 586
Chertow, G.M., 217, 507
Cherubini, C., 546
Chiang, H.W., 2:E6
Chikamoto, H., 1121
Chiu, Y.S., 2:E6
Cho, D.-K., 2:E7
Cho, Y.-J., 2:E7
Chow, K.-M., 5:xlviii, 567, 781
Chu, P., 1221
Chua, B.S.Y., 1260
Chuang, F.-R., 524
Chung, J.-H., 6:E26
Chvala, R., 315
Cigni, A., 3:E11
Clark, W.F., S1:49

AUTHOR INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number.

Page references to Supplement 1 (July 2003), Supplement 2 (July 2003), Supplement 3 (October 2003), Supplement 4 (November 2003), and Supplement 5 (December 2003) are preceded, respectively, by S1:, S2:, S3:, S4:, and S5:.

Abbott, K.C., 1058
Abe, K., 76
Abraham, M., 797
Abramson, F., 561
Abul-Ezz, S.R., 202
Adachi, M., 1287
Adler, S.G., 395
Agodoa, L.Y., 1058
Aguilera, A., 787
Ahuja, T.S., 376
Akiba, T., 303
Akioka, Y., 1121
Alhejaili, F., S1:24
Al-Hilali, N., 797
Allen, A.S., 1260
Allon, M., 388, 612
Al Mousawi, M., 797
Al-Muzeirei, I.A., 797
Alpers, C.E., 605
Al-Shamari, A., 591
Amadori, F., 3:E11
Ambühl, P.M., 193
Ammann, P., 193
Anderson, P.W., 456
André, J.-L., 5:E19
Andreoni, K., 5:E23
Anger, M.S., 315
Ankenbrandt, M., 926
Antignac, C., 1:E2
Appel, L.J., 256
Arakawa, H., 271
Araki, S.-i., 943
Arcidiacono, T., 1177
Arnold, R.M., 813
Ars, E., 952
Ascher, N.L., 362
Ashizawa, M., 76
Asif, A., 229, 1270, 1293
Avram, M.M., 864
Ayanian, J.Z., 1043
Azzi, A., 821
Badalamenti, S., 143
Badenas, C., 952
Bae, K., 2:E7
Baek, H.W., 6:E26
Bagga, A., 1114
Baggio, E., 331
Baines, L.S., 431
Bajo, M.A., 787
Bakris, G.L., 617, 1301
Balducci, A., 1036
Baliga, S., 532
Ballanti, P., 1036
Bankhurst, A., 1212
Barone, G.W., 202
Barré, P.E., 693
Bartlett, C., 551
Barz, A., 752
Baumgarten, D.A., 601
Beck, G.J., 44
Becker, B., 62
Becker, D.J., 117
Bedogni, V., 331
Bendel, K.J., 3:xlviii
Bennett, W.M., 217
Benoit, M.O., 513
Bergstrahl, E.J., 685
Berns, J.S., 325
Berto, I.M., 67
Bhattacharia, K.F., 3:E17
Bianchin, C., 1177
Bihorac, A., 704
Binik, Y.M., 693
Blagg, C.R., S1:1
Blake, P.G., S1:42
Bleyer, A.J., 2:E8
Blinder, J., 1:lxix
Block, G., 864
Block, S.D., 813
Boczuła, M., 539
Boero, R., 67
Bonucci, E., 1036
Bosnyak, Z., 117
Bourgoignie, J.J., 1270, 1293
Bowden, D.W., 133
Brabant, G., 62
Brancaccio, D., 143
Brancati, F.L., 249, 256
Brayman, K., 1000
Bredi, E., 143
Brémont-Gignac, D., 5:E19
Brewster, P.S., 926
Briançon, S., 474
Brophy, P.D., 1248
Brown, W.W., 22
Buisson, C., 513
Bulucu, F., 1164
Bunchman, T.E., 1248
Burding, J.E., 234
Burket, M.W., 926
Burkhart, J., 1082
Burnett, S., 1184
Burns, A., 582
Burns, J.E., 1000
Byers, P., 229, 1270
Cai, W., 532
Calabria, S., 1036
Calonge, V.M., 513
Campbell, D.A. Jr., 151
Campbell, H., 3:E15
Carmody, S.S., 813
Carpenter, B., 1107
Carrie, B.J., 1020
Cass, A., 1043
Castro, M.J., 787
Catalano, C., 722
Catania, A., 143
Cattran, D.C., 846
Cauci, F., 3:E11
Cavallone, D., 658
Cecka, J.M., 882
Celadilla, O., 787
Cernelc, P., 746
Cetin, T., 1164
Chalermkulrat, W., 1149
Chan, L.Y.Y., 173
Chan, T.M., 173
Chang, C.-F., 3:E14
Chapman, A.B., 1305
Charbonneau, P., 497
Charest, A.F., 1193
Charney, D.A., 1097
Chen, C.-H., 990
Chen, J.-Y., 3:E14
Chen, M.L.W., 623
Chen, S.-C., 22
Chen, W.-T., 158
Chen, Y.-C., 586
Chertow, G.M., 217, 507
Cherubini, C., 546
Chiang, H.W., 2:E6
Chikamoto, H., 1121
Chiu, Y.S., 2:E6
Cho, D.-K., 2:E7
Cho, Y.-J., 2:E7
Chow, K.-M., 5:xlviii, 567, 781
Chu, P., 1221
Chua, B.S.Y., 1260
Chuang, F.-R., 524
Chung, J.-H., 6:E26
Chvala, R., 315
Cigni, A., 3:E11
Clark, W.F., S1:49

Clement, L., S1:24, 56
 Codoceo, R., 787
 Coen, G., 1036
 Cohen, L.M., 813
 Cointault, O., 184
 Colamarco, L., 1036
 Colicigno, C.J., 133
 Colindres, R.E., 6:E25
 Collins, A., 22
 Collins, A.J., 972, 1013, 1275
 Colville, D., 2:E3
 Colyer, W.R., 926
 Comandini, U.V., 546
 Como, G., 143
 Comoli, P., 821
 Comoz, F., 4:E18
 Contreras, G., 315
 Cooper, C.J., 926
 Coresh, J., 108, 256, 623
 Counts, C., 12
 Covini, G., 143
 Cozzupoli, P., 722
 Crikis, S., 207
 Critchlow, C.W., 982
 Cunningham, J., 1043
 Curioni, S., 1154
 Cusi, D., 1177
 Cutrupi, S., 722

D'Agati, V.D., 419
 Dahl, D., 1013
 D'Amico, M., 1154
 Danielski, M., 286
 Danko, H., 713
 Danovitch, G.M., 882
 Darnell, A., 952
 DaRoza, G., 1184
 Das, K.C., 797
 Daubin, C., 497
 Daugirdas, J.T., 1200
 Davies, D.R., 842
 Davison, S.N., 1239
 Dedi, R., 3:E15
 de Ligny, B.H., 4:E18
 DeLong, M.J., 381
 Depner, T.A., S1:42
 de Santis, R., 821
 Devins, G.M., 693
 Di Giulio, S., 546
 Ding, P.Y.-A., 990
 Di Zazzo, G., 1036
 Djurdjev, O., 1184
 Dodd, M., 362
 Dorman, J.S., 117
 Dosekun, A.K., 3:E13
 Drey, N., 677
 Drukker, A., 1107
 du Cheyron, D., 497
 Durand, D., 184

Easow, S., 797
 Easterling, T.R., 982
 Ebben, J., 972
 Ebben, J.P., 1013
 Eberhardt, M.S., 249, 256
 Eknoyan, G., 617
 Ellekjaer, H., 466
 El Menyawi, I., 310
 Elzinga, L., 315
 Emont, S.L., 713
 Endou, H., 1287
 Erlinger, T.P., 256
 Espinoza, M., 787

Faedda, R., 3:E11
 Falk, R.J., 1149
 Farres, M.T., 1:E2
 Feber, J., 1107
 Fehr, T., 193
 Feldman, H.I., 1000
 Felicioni, R., 546
 Feng, L., 575
 Ferguson, E., S1:56
 Fernandez, J.S., 446
 Ferrando, A., 1212
 Ferrario, F., 1154
 Filler, G., 1107
 Fink, N.E., 108
 Finkelstein, F.O., 350
 Finn, L.S., 1318
 Finn, W.F., 96
 Firpo, M., 331
 Fischer, M.S., 1036
 Flack, J.M., 22
 Fliser, D., 62
 Fochesato, E., 1177
 Fogazzi, G.B., 1154
 Fogo, A.B., 87, 2:xli, 826
 Fontana, I., 821
 Franke, J., 936
 Frankenstein, D.L., 806
 Franssila, K., 960
 Frederick, P.R., 806
 Freedman, B.I., 133
 Freitas, T., 1020
 Friedman, E.A., 2:E4
 Frimat, L., 474
 Froio, N., 546
 Frye, R.F., 906
 Fuchinoue, S., 739
 Fuhrmann, V., 310
 Fujimoto, S.-i., 5:E20
 Fukazawa, A., 1121
 Fumeron, C., 513
 Funovics, M., 539
 Furusu, A., 76

Gadalean, F., 1270
 Gadallah, M.F., 1270
 Gammaro, L., 331
 Gansevoort, R.T., 3:xlviii

García, J., 53, 264
 García, P., 787
 Garg, J., 1301
 Gaziano, J.M., 234
 Geier, P., 1107
 Gerstein, H.C., 936
 Ghaddar, S., 325
 Ghali, W.A., 125
 Ghoneim, M.A., 370
 Giaculli, F., 108
 Giambona, S., 1177
 Gibney, E.M., 1
 Gilbertson, D., 1275
 Gillen, D.L., 982
 Ginevri, F., 821
 Glynn, R.J., 234
 Goga, T., 2:E10
 Gohdes, D., 245
 Gökdén, N., 202
 Goldberg, T., 532
 Goldfarb, D.S., 1
 Goldstein, M.B., 1193
 Goodman, D.G., 207
 Gorban-Brennan, N., 350
 Gorry, M.C., 2:E8
 Gotch, F., 167
 Gotoh, T., 5:E20
 Graf, S., 62
 Grand'Maison, A., 1193
 Grantham, J.J., 427
 Graziani, G., 143
 Greenbaum, L.A., 5:E22
 Greene, T., 44, 1200
 Griffith, T.F., 1260
 Grönhagen-Riska, C., 1139
 Groundstroem, K., 277
 Grüter, E., 193
 Gurley, B.J., 202
 Guymer, R., 2:E3
 Gyamlani, G.G., 685

Haddad, E., 5:E19
 Hallan, H., 466
 Haller, H., 62
 Hamaoka, K., 5:E20
 Hamburger, R.J., 342
 Haneda, M., 943
 Harada, T., 76
 Hare, J.M., 891
 Hari, P., 1114
 Hart, T.C., 2:E8
 Hartley, B., 3:E15
 Harwell, T.S., 245
 Hattori, M., 1121
 Hayashi, F., 3:E12
 Hebert, L., 617
 Hector, L., 362
 Heidenheim, A.P., S1:5, 24, 30, 36,
 42, 49, 56, 61
 Heinze, G., 539
 Heiro, M., 960

Helgerson, S.D., 245
 Hemmelgarn, B.R., 125
 Henke, D.C., 1149
 Henke, P., 151
 Hennekens, C.H., 234
 Hibi, I., 295
 Higami, Y., 1:E1
 Hiki, Y., 486
 Hill, P., 842
 Hill, P.A., 207
 Himmelfarb, J., 286, 507
 Hirakawa, S., 133
 Hishida, A., 2:E10, 3:E16
 Ho, S.K.N., 173
 Ho, Y.W., 5:E21
 Hoenich, N.A., 167
 Hogan, S.L., 1149
 Holley, J.L., 813
 Holmen, J., 466
 Honkanen, E., 1139
 Hoofnagle, J.H., 631
 Hoogwerf, B.J., 936
 Horie, A., 486
 Horn, R.G., 87
 Hosoyamada, M., 1287
 Hostetter, T., 617
 Hostetter, T.H., 392
 Houillier, P., 497
 Hsu, C.-y., 623
 Hsu, T.-L., 990
 Hsu, Y.-J., 774
 Huang, C.-C., 524
 Huang, C.Y., 2:E6
 Huang, W.H., 158
 Huhtala, H., 277
 Hung, Y.-J., 774
 Hurtado, A., 575
 Hutchison, F., 12
 Ibrahim, H.N., 1275
 Ihm, C.G., 6:E26
 Ikegaya, N., 295
 Ikizler, T.A., 286, 507, 864
 Ilamathi, M.E., 419
 Iliou, M.C., 513
 Inou, T., 729
 Irjala, K., 36
 Ishani, A., 1275
 Isoaho, R., 36
 Isomoto, H., 76
 Isozaki, T., 3:E16
 Ito, K., 1121
 Itoh, K., 1287
 Iwase, H., 486
 Iyoda, M., 3:E12
 Izopet, J., 184
 Jacob, L., 1:E2
 Jacquot, C., 513
 Jeon, K., 2:E7
 Jindal, R.M., 431
 Joffe, M., 1000
 Johnson, A., 561
 Johnson, R.J., 575
 Johny, K.V., 797
 Jones, S.A., 752
 Jordan, S.C., 1114
 Joseph, J.T., 431
 Joy, M.S., 96
 Kabaya, T., 303
 Kaehny, W.D., 2:E5
 Kaizu, Y., 295
 Kalantar-Zadeh, K., 761, 864
 Kamar, N., 184
 Kane, J.C., 286
 Kanetake, H., 1:E1
 Kao, J.-T., 3:E14
 Kao, W.-Y., 158
 Karim, M., 842
 Kashiwagi, A., 943
 Kato, A., 2:E10
 Kato, M., 486
 Kausz, A.T., 972
 Kawaguchi, H., 1121
 Kawakatsu, H., 5:E20
 Kawasaki, Y., 1131
 Kawashima, A., 303
 Kayler, L.K., 151
 Kays, M.B., 342, 1253
 Kaysen, G., 167
 Kaysen, G.A., 1200
 Keane, W.F., 22
 Kempston, C., 1184
 Kennedy, D.J., 926
 Kessler, M., 474
 Kestenbaum, B., 982
 Khono, M., 1121
 Khuder, S.A., 926
 Kiaii, M., 1184
 Kielstein, J.T., 62
 Kim, M.J., 6:E26
 Kim, Y.-L., 2:E7
 Kimmel, P.L., 713, 1200
 King, K., 22
 Kiser, R.L., 5:E23
 Kissner, P.Z., 6:E24
 Kitamura, K., 1287
 Kitazawa, K., 3:E12
 Kivelä, S.-L., 36
 Kjellstrand, C., 1020
 Klag, M.J., 22, 108
 Klarenbach, S., 51:18
 Klassen, P.S., 1260
 Klemmer, P.J., 1149, 5:E23
 Kliger, A.S., 350
 Knauss, J., 1000
 Kobayashi, Y., 271, 486
 Koç, M., 704
 Kocar, I.H., 1164
 Koga, S., 1:E1
 Kohno, S., 76
 Koji, T., 76
 Kolon, T., 1:xlix
 Kopple, J.D., 761, 864
 Kortas, C., S1:5, 13, 24, 61, 66
 Koskinen, P., 1139
 Kovarik, J., 539
 Kowalewska, J., 605
 Koya, D., 943
 Kroeker, A., S1:49
 Kuenzig, L., S1:49
 Kumagai, H., 295
 Kuo, S.-W., 774
 Kurella, M., 217
 Kuroki, A., 3:E12
 Kurt, I., 1164
 Kurth, T., 234
 Kusek, J.W., 44
 Kvenild, K., 466
 Kwan, B.C.-H., 1069
 Laboi, P., 3:E15
 Lai, K.-B., 781
 Lai, K.N., 173
 Lanfranco, G., 67
 Lange, E.M., 133
 Lapeyraque, A.-L., 5:E19
 Larson, T.S., 685
 Leavy, S., 151
 Leechi, P., 561
 Leclercq, B., 1270, 1293
 Lee, G.H., 761
 Lee, J., 315
 Lee, S., 1169
 Lee, S.H., 6:E26
 Lee, T.W., 6:E26
 Le Goas, F., 1:E2
 Lehn, R.S., 761
 Lehtimäki, T., 277
 Leitch, R., S1:5, 24, 49, 56, 61
 Lens, X., 952
 Leskinen, Y., 277
 Leung, C.-B., 567, 1069
 Levey, A.S., 44, 108, 617, 623
 Levi, M., 2:E5
 Levin, A., 591, 1184
 Levin, N.W., 167, 1200
 Lew, S.Q., 561
 Li, F.K., 173
 Li, H.-Y., 586
 Li, P. K.-T., 567, 781, 1069
 Li, P. K.T., 5:xlviii
 Lien, Y.-H.H., 381
 Lifrieri, F., 1036
 Lin, C.-C., 3:E14, 586
 Lin, C.-L., 524
 Lin, S.-H., 586, 774, 1221
 Lin, Y.-F., 158, 774
 Lin, Y.-P., 990
 Linas, S.L., 215
 Lindsay, R.M., S1:56
 Lindley, E.J., 551

Lindsay, R.M., S1:3, 5, 13, 18, 24, 30, 36, 42, 49, 61, 66
 Lipari, G., 331
 Little, R.R., 245
 Liu, P.-Y., 315
 Lo, K.-Y., 1075
 Lo, W.K., 173
 Lobbedez, T., 4:E18
 Locatelli, F., 821, 1154
 Loewen, A., 1184
 Loirat, C., 5:E19
 Longenecker, J.C., 108
 Lonn, E.M., 936
 Lorenz, M., 539
 Losurdo, G., 821
 Love, J., 1184
 Lu, K.-C., 1221
 Lu, M., 532
 Luckisri, A., 342
 Luft, F.C., 1283
 Lunghi, G., 143
 Lynes, L., 362
 Maca, T., 539
 Macario, R., 821
 Macia, M., 53, 264
 Maeda, K., 486
 Maeda, S., 943
 Maes, B., 4:xli
 Magil, A., 591
 Magnasco, A., 752
 Mak, S.-K., 1075
 Makishi, T., 943
 Malagolini, N., 658
 Manca, A., 3:E11
 Mange, K.C., 1050
 Mann, J.F.E., 936
 Manni, M., 1036
 Mans, B.J., 125
 Mansuetu, G., 331
 Marcovina, S.M., 44, 108
 Marcussen, N., 960
 Marino, C., 722
 Markowitz, G.S., 419
 Mars, R.L., 315
 Martin, J.L., 6:E25
 Martorano, C., 722
 Marx, C., 1283
 Marx, M., 1283
 Maschio, G., 331
 Massara, C., 67
 Matsunaga, A., 1121
 Matsuo, M., 1:E1
 Matsushita, K., 1287
 Mattila, K., 36
 Matzke, G.R., 906
 Maxvold, N.J., 1248
 McAllister, C.J., 761
 McClellan, W.M., 806
 McDougall, J., 1193
 McDowall, J.M., 245
 McMonagle, E., 286
 Mehrabian, S., S1:66
 Mehta, R.L., 507
 Meier, P., 1:E2
 Mendelsohn, D.C., 693
 Menon, V., 44
 Merion, R.M., 151
 Merrill, D., 1270, 1293
 Merszei, J., 575
 Meyers, C.M., 631
 Meyers, K., 1:xlix
 Meyette, M., S1:49
 Migdal, S.D., 6:E24
 Mignogna, G., 1177
 Milà, M., 952
 Minagawa, T., 355
 Mishkin, G.J., 561
 Mishkin, M., 561
 Mitterbauer, C., 539
 Mittermayer, C., 310
 Mix, T.-C. H., 972
 Miyaji, K., 295
 Miyakawa, S., 1121
 Miyazaki, M., 76
 Moatti, N., 513
 Moe, S.M., 1253
 Mohamed, N.A.-H., 370
 Moist, L., S1:13, 18, 36
 Mollura, D.J., 891
 Molony, D.A., 22
 Moore, G.M., 325
 Mora, C., 53, 264
 Morana, G., 331
 Morgan, D., S1:66
 Morikawa, A., 271
 Morris, M.C., 431
 Morrow, J., 286
 Moss, A.H., 713, 813
 Moudgil, A., 1114
 Mougenot, B., 1:E2
 Mueller, B.A., 342, 1253
 Muirhead, N., S1:18, 36, 49
 Mullee, M., 677
 Muros, M., 264
 Murphy, L., 167
 Musabak, U., 1164
 Nakakura, H., 1121
 Nakamura, M., 739
 Nakashima, I., 486
 Nampoory, M.R.N., 797
 Nasr, S.H., 419
 Navarro, J.F., 53, 264
 Nelson, R.G., 245
 Nemeth, A.S., 926
 Nesrallah, G., S1:13, 24
 Newmann, J.M., 713
 Nicastri, E., 546
 Nigg, L., 193
 Nihei, H., 303
 Nishida, M., 5:E20
 Nishimura, R., 117
 Nissenson, A.R., 325, 761
 Nitta, K., 303
 Nofroni, I., 1036
 Nolan, C.R., 1169
 Nolin, T.D., 906
 Nonoguchi, H., 1287
 Oberbauer, R., 539
 Oda, H., 355
 Odamaki, M., 295
 Odani, H., 486
 Oei, L.S., 2:E9
 Ogawa, Y., 729
 Ogino, D., 1121
 Oguz, Y., 1164
 Ohashi, H., 355
 Ohashi, N., 3:E16
 Ohkawa, S., 295
 Ohkuma, T., 355
 Ohmit, S.E., 22
 Ohno, M., 355
 Ohtani, H., 1:E1
 Oksa, H., 1228
 Oktenli, C., 1164
 Olveira, A., 787
 O'Neill, W.C., 601
 Ono, T., 5:E20
 Orchard, T.J., 117
 Otsubo, O., 729
 Ouwendyk, M., S1:56
 Overholser, B.R., 1253
 Owen, W.F. Jr., 806
 Ozgurtas, T., 1164
 Ozono, Y., 76
 Paganini, E.P., 507
 Paillard, M., 497
 Painter, P.L., 362
 Paiva, A.M., 787
 Panescu, V., 474
 Pangilinan, A., 167
 Park, S.-H., 2:E7
 Parving, H.-H., 617
 Pascual, M.T., 507
 Pasquali, S., 1154
 Pasternack, A., 1228
 Pastorino, N., 821
 Patel, B., 1324
 Pauksakon, P., 87
 Paul, S.M., 362
 Paulson, W.D., 752
 Penumalae, S., 6:E24
 Peppa, M., 532
 Pereira, B.J.G., 972
 Perfumo, F., 821
 Pergola, P.E., 1169
 Perosa, P., 67
 Peters, K., S1:56
 Peters, R.M., 22
 Petrosillo, N., 546

Ploin, P.-F., 851
 Plot, D.W., 12
 Poggioli, J., 497
 Poli, A., 331
 Ponikvar, J.B., 746
 Ponticelli, C., 143
 Popovtzer, M.M., 2:E5
 Postorino, M., 722
 Powe, N.R., 108, 249, 256
 Pozzi, C., 1154
 Pujo, M., 4:E18
 Pulliam, J., 315
 Pupim, L., 286

Quan, H., 125
 Quarello, F., 67
 Quattrochcio, G., 1154

Rabb, H., 599, 891
 Raj, D.S.C., 1212
 Ram, S.J., 752
 Ramakers, M., 497
 Ramakumar, S., 381
 Rao, M., S1:18
 Rashkow, A., 936
 Rattheiser, K., 310
 Ray, K., 362
 Reddan, D.N., 1260
 Refaie, A.F., 370
 Reif, M.S., 1149
 Reina, T., 1228
 Renaudineau, E., 4:E18
 Renner, E.L., 193
 Revelo, M.P., 87
 Rexrode, K.M., 234
 Reynolds, J.C., 1058
 Rianthavorn, P., 5:E19
 Ribes, D., 184
 Rich, S.S., 133
 Richardson, D., 551
 Riehle, H.-M., 193
 Riley, D.J., 1169
 Rizk, D., 1305
 Robert, N., 315
 Roberts, I.S.D., 842
 Roderick, P., 677
 Rodriguez-Iturbe, B., 575
 Rogerson, M., 677
 Rollino, C., 67, 1154
 Romundstad, S., 466
 Ronco, C., 167
 Ronco, P., 1:E2
 Rosas, S.E., 1000
 Rostaing, L., 184
 Roth, D., 229, 1270, 1293
 Rubinacci, A., 1177
 Ruutu, M., 1139
 Ryan, H., S1:49
 Ryckelynck, J.-P., 4:E18

Šabovic, M., 746
 Sadaniantz, A., 446
 Sadaniantz, B.T., 446
 Saed, T., 797
 Saha, H., 277
 Sahani, M., 2:E9
 Sakai, H., 76
 Sakai, N., 1131
 Sakai, O., 3:E12
 Sakiewicz, P., 325
 Salant, D.J., 395
 Salobir, B., 746
 Salonen, T., 1228
 Salusky, I.B., 5:E19
 Salvadori, M., 143
 Sánchez, S., 787
 Sandhu, J., 2:E8
 Sandres-Saune, K., 184
 Sanisoglu, S.Y., 1164
 Santacroce, S., 167
 Santopietro, A., 821
 Sardella, D., 1036
 Sarnak, M.J., 44, 596
 Satta, A.E., 3:E11
 Savage, B.R., 507
 Savige, J., 2:E3
 Schenk, P., 310
 Schlaeper, C., S1:66
 Schleicher, R.B., 325
 Schmitt, D., 381
 Schneditz, D., 167
 Schnuelle, P., 385
 Schulman, G.W., 1200
 Schwartz, S.M., 982
 Schwarz, C., 539
 Scott, K.M., 381
 Scott, M.K., 342
 Scudo, P., 722
 Seeff, L.B., 631
 Segagni, S., 1154
 Segal, J.H., 151
 Segal, M.S., 704
 Selgas, R., 787
 Seliger, S.L., 982
 Seligman, P.A., 325
 Selves, J., 184
 Sementa, A., 821
 Serafini-Cessi, F., 658
 Serna, J.H., 3:E13
 Sethi, S., 2:E9
 Shafritz, R., 315
 Shah, H., 1212
 Shah, V.O., 1212
 Shapiro, J.I., 926
 Shappell, S., 87
 Sheashaa, A., 370
 Sheerin, N.S., 3:E17
 Shemin, D., 315
 Shepp, P.H., 12
 Sheriff, A.M., 370
 Shiao, M.-S., 3:E14

Shibata, T., 3:E12
 Shimokawa, I., 1:E1
 Shinozaki, S., 2:E10
 Shiraiishi, I., 5:E20
 Sinclair, R.A., 2:E3
 Sintonen, H., 1228
 Skluzacek, P.A., 1169
 Slezak, J.M., 685
 Smith, J.M., 1318
 Snelling, P., 1043
 Sobh, M.A.-K., 370
 Soldati, L., 1177
 Solmone, M., 546
 Soro, G., 3:E11
 Soroko, S., 507
 Sowinski, K.M., 342, 1253
 Spanner, E., S1:30
 St. Peter, W. L., 972
 Stampfer, M.J., 234
 Stassen, P.M., 3:xlviii
 States, L., 1:xlix
 Steffes, M.W., 617
 Stehman-Breen, C.O., 631, 982
 Sugarman, J.R., 806
 Sugathan, T.N., 797
 Sugasaki, T., 3:E12
 Sugiura, T., 3:E16
 Sullivan, A.M., 813
 Suri, R., S1:13, 30, 42
 Suzuki, H., 1131
 Suzuki, J., 1131
 Suzuki, M., 271
 Swamy, S., 752
 Symons, J.M., 1318
 Szczecz, L.A., 1260
 Szeto, C.-C., 567, 781, 1069
 Szeto, C.Y.-K., 781
 Szewc, R.G., 1169

Taber, T.E., 315
 Tajima, N., 117
 Takada, N., 355
 Takahashi, H.E., 729
 Takahashi, M., 486
 Takizawa, T., 271
 Tam, M.K., 5:E21
 Tanaka, M., 1287
 Tanda, F., 3:E11
 Tang, A.W.C., 5:E21
 Tang, S., 5:E21
 Tanji, M., 1131
 Tarver-Carr, M.E., 249, 256
 Taylor, C.M., 5:E19
 Taylor, J.G.C., 2:E5
 Taylor, P., 591
 Taylor, P.A., 1184
 Tedla, F.M., 2:E4
 Teitelbaum, I., 1082
 Teppo, A.-M., 1139
 Teraoka, S., 739
 Terranegra, A., 1177

Tessitore, N., 331
 Textor, S.C., 858
 Thalhammer, F., 310
 Thomas, D., 6:E25
 Thomas, D.B., 5:E23
 Thomas, W.J., 926
 Thompson, B., 582
 Ting, G.O., 1020
 Tokuyama, K., 271
 Tomford, R.C., 605
 Tominaga, Y., 729
 Tomita, K., 1287
 Tomlanovich, S.L., 362
 Tong, G.M.W., 1075
 Törnroth, T., 960, 1139
 Torra, R., 952
 Toth, H.L., 5:E22
 Toto, R., 617
 Toto, R.D., 1200
 Trachtman, H., 2:E8
 Troidle, L., 350
 Tsai, T.J., 2:E6
 Tuppin, P., 513
 Turney, J.H., 3:E15
 Tuttle, K.R., 456
 Uchida, K., 303
 Urata, Y., 5:E20
 Uribarri, J., 532
 Vagelli, G., 67
 Vahlberg, T., 36
 van Baarlen, J., 3:xlviii
 Vandermarliere, A., 4:xli
 van der Woude, F.J., 385
 van Poelgeest, B.E., 3:xlviii
 Vanrenterghem, Y., 4:xli
 van Willebrand, E., 1139
 Vassalotti, J.A., 532
 Vega, B.T., 952
 Vesely, T., 315
 Vezzoli, G., 1177
 Vieira, C.F., 229, 1270
 Virtanen, V., 277
 Vlassara, H., 532
 Wakita, N., 1287
 Walker, A.M., 234
 Wang, A.Y.-M., 1069
 Wang, X., 44
 Wanger, A., 3:E13
 Warnock, D.G., 388
 Wasén, E., 36
 Wasser, W., 1097
 Watanabe, J.-i., 1:E1
 Watnick, S., 350
 Watt, C.-L., 1075
 Webb, M.C., 3:E17
 Weiner, D.E., 596
 Welch, R., S1:49
 Weng, F.L., 1050
 White, S., S1:49
 Will, E.J., 551
 Winearls, C.G., 842
 Wolfe, R., 1212
 Wong, A.K.M., 1075
 Wong, P.-N., 1075
 Wong, T.Y.-H., 567, 781
 Wong, Y., 1075
 Woo, J.C.Y., 173
 Wuerth, D.B., 350
 Xue, J., 972
 Xue, J.L., 1013
 Yajima, A., 729
 Yamamoto, T., 3:E16
 Yan, G., 1200
 Yan, H.-C., 158
 Yang, A.-H., 3:E14, 586
 Yang, C.-W., 524
 Yang, H.-Y., 524
 Yang, W.-C., 3:E14, 586, 990
 Yasuda, Y., 486
 Yenicesu, M., 1164
 Yeung, K., 591
 Yeung, L.-K., 1221
 Yi, Q.-L., 936
 Yildiz, O., 1164
 Yoo, T.-H., 6:E26
 Yoon, K.S., 6:E26
 Young, E., 1107
 Yu, C.-C., 524
 Yu, F.-C., 158
 Yu, W.-C., 990
 Yuan, C.M., 1058
 Yumura, W., 303
 Yusuf, S., 936
 Zager, P.G., 1212
 Zarghami, S., 1020
 Zhu, F., 167
 Zoccali, C., 722
 Zsom, L., 752
 Zupan, I.P., 746
 Zwillich, C.W., 2:E5

SUBJECT INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number.

Page references to Supplement 1 (July 2003), Supplement 2 (July 2003), Supplement 3 (October 2003), Supplement 4 (November 2003), and Supplement 5 (December 2003) are preceded, respectively, by S1:, S2:, S3:, S4:, and S5:.

Access, vascular. *See* Vascular access
 Access to care
 kidney transplantation, late referral to nephrologist and, 1043–1049
 socioeconomic status and, 249–255
 Accreditation Counsel for Graduate Medical Education, core nephrology curriculum and, 215–216
 ACE inhibitors. *See* Angiotensin-converting enzyme inhibitors
 Acetaminophen
 in end-stage renal disease, 217–228
 kidney function changes in healthy men and, 234–244
N-Acetyl-b-glucosaminidase excretion in type 2 diabetes, pentoxifylline effects on, 264–270
 Acidosis
 caused by starvation and stress, 5:E22
 metabolic, S3:129–130
 Acquired reactive perforating collagenosis, allopurinol therapy for nondiabetic HD patient, 3:E12
 ACR. *See* Albumin-creatinine ratio
 Acute coronary syndromes, antithrombotic agents for renal patients and, 446–455

Acute renal failure (ARF)
 after retrograde pyelography, 2:E6
 cohort study, reasons for nonenrollment in, 507–512
 early, novel urinary markers for, 599–600
 exercise-induced, with familial renal hypourcemia, 1287–1292
 in renal lymphoma, diagnosis by percutaneous kidney biopsy, 960–971
 tubule injury, NHE3 as marker for, 497–506

Acute tubular necrosis, NHE3 protein as marker for, 497–506

Adequacy
 of peritoneal dialysis, 1082–1096
 of quotidian hemodialysis, S1:42–48

ADPKD (autosomal dominant polycystic kidney disease), nephrology core curriculum, 1305–1317

Adrenocorticotropic hormone deficiency, presenting with hypercalcemia, 2:E10

Adult-onset tubulointerstitial nephritis and uveitis, with sarcoidosis and EBV infection, 3:E11

Advanced glycation end products (AGEs)
 circulating in renal failure, dietary glycotoxins and, 532–538
 reduction by on-line hemodialfiltration in long-term hemodialysis, 524–531

Adynamic bone disease, K/DOQI Clinical Practice Guidelines, S3:125–127

African Americans
 HIV-positive male, immunotactoid glomerulopathy in, 6:E25
 matrix metalloproteinase 9 gene in ESRD, 133–142
 receipt of renal replacement therapy and, 249–255

Age
 chronic kidney disease risk and, S4:34–S4:41
 prognosis for LCDD with renal involvement, 1154–1163
 thrombotic microangiopathy after renal transplantation and, 1058–1068

AGEs. *See* Advanced glycation end products

AKRIB1 C-106T polymorphism, in diabetic nephropathy, 943–951

Alarms, for nocturnal hemodialysis monitoring, S1:61–65

Albumin, serum
 correlation with enPCR and CRP, 1200–1211
 CRP levels chronic kidney disease and, 44–52
 hypoalbuminemia
 chronic kidney disease and, 256–263
 inflammation and oxidative stress in maintenance HD, 286–294
 quality of life in ESRD and, 713–721
 in quotidian hemodialysis, S1:30–35

Albumin, urinary. *See* Microalbuminuria

Albumin-creatinine ratio (ACR)
 health status of elderly and, 36–43
 in microalbuminuria testing, 245–248

Albumin osmolality ratio, in predicting 24-hour urine albumin excretion in diabetes mellitus, 685–692

Albuminuria. *See* Microalbuminuria

Aldose reductase, in Japanese patients with type 2 diabetes, 943–951

Alkalosis, metabolic hypochloremic, after small bowel transplant rejection-related diarrhea, 1283–1286

Allergic disease, interleukin-4-related gene polymorphisms and, 271–276

Allocation algorithm development, for kidney transplantation, 882–890

Allograft, renal
 dysfunction, dense deposit disease and, 207–211
 HBV and HCV-infected, evaluation of, 193–201
 loss, in BKV-associated interstitial nephritis, retransplantation after, 821–825
 mortality in elderly ESRD patients and, 1013–1019
 multicentric papillary renal carcinoma in, 381–384
 preexisting crescentic glomerulonephritis in, 5:E23
 survival, residual renal function in preemptive kidney transplantation and, 1275–1282

Allopurinol, for acquired reactive perforating collagenosis in nondiabetic HD patient, 3:E12

Alport's syndrome
 nephrology core curriculum, 1305–1317
 retransplantation after polyoma BK virus-associated allograft loss, 821–825

Aluminum, overload and toxicity in CKD
 clinical features and therapeutic considerations, S3:108–116
 treatment algorithm, S3:116–122

Amino acids
 in CAPD dialysate, long-term study of, 173–183
 in ESRD hemodialysis patients, 1212–1220

Amphotericin B, for mucormycosis peritonitis during long-term PD, 3:E13

Amyloidosis, long-term outcome of kidney transplant, 370–375

Analgesic usage
 in ESRD, 217–228
 kidney function changes in healthy men and, 234–244
 for pain in hemodialysis, 1239–1247
 renal disease in postphenacetin era and, 385–387

ANCA-positive glomerulonephritis
 associated with minocycline, E9
 recurrence after kidney transplantation, 4:E18

Anderson-Fabry disease, nephrology core curriculum, 1305–1317

Anemia
 in chronic kidney disease, KEEP program participants and, S4:49–S4:56
 heme iron polypeptide in HD patients, 325–330
 malnutrition-inflammation complex syndrome in dialysis and, 864–881
 management in quotidian hemodialysis, S1:18–23
 renal tubular dysfunction in β -thalassemia minor, 1164–1168

Angiotensin-converting enzyme (ACE) inhibitors
 for atherosclerotic renal artery stenosis, 851–857
 with calcium channel blockers for nondiabetic nephropathy, 67–75
 for cardiovascular risk reduction in dialysis patients, 1301–1304
 progression of renal insufficiency in type 2 diabetes mellitus, 936–942

Animal models of diabetic nephropathy, ruboxistaurin effects in, 456–465

Annexin-V expression, in ESRD hemodialysis patients, 1212–1220

Anterior ischemic optic neuropathy, in pediatric chronic peritoneal dialysis, 5:E19

Antibody titer, natural hepatitis B immunity in long-term HD patients, 1193–1199

Anticoagulant Citrate Dextrose Solution Formula A with Normocarb, for pediatric CVVH, 1248–1252

Anticonvulsants, in end-stage renal disease, 217–228

Antidepressants, in end-stage renal disease, 217–228

Anti-glomerular basement membrane nephritis
 dual pattern of immunofluorescence positivity, 419–426
 with periglomerular granulomatous reaction and eosinophilic infiltration, 3:E16

Antihypertensive drugs
 for hypertension treatment in incident HD and PD, 1260–1269
 utilization to reduce cardiovascular risk in dialysis patients, 1301–1304

Antineutrophil cytoplasmic antibodies, plasmapheresis for small-vessel vasculitis diffuse alveolar hemorrhage, 1149–1153

Antiplatelet drugs, for acute coronary syndromes in renal patients, 446–455

Antithrombotic agents, for acute coronary syndromes in renal patients, 446–455

Aortic atherosclerosis, in chronic renal failure, 277–285

Apheresis
 for diffuse alveolar hemorrhage in small-vessel vasculitis, 1149–1153
 LDL, for children with steroid-resistant FSGS, 1121–1130
 triple- vs. dual-lumen catheters for, 315–324

Apolipoprotein(a), atherosclerotic cardiovascular disease in dialysis patients and, 108–116

Apolipoprotein E3/3, in protein glomerulopathy with psoriasis vulgaris, 3:E14

Apoptosis, in ESRD hemodialysis patients, 1212–1220

ARF. *See* Acute renal failure

ARPKD (autosomal recessive polycystic kidney disease), nephrology core curriculum, 1305–1317

Arteriosclerosis
 large-artery, ECF-ICF ratio in HD patients and, 990–999
 progression of renal insufficiency in type 2 diabetes mellitus, 936–942

Arteriovenous fistula (AVF)
 creation by nephrologists, 1293–1300
 stenosis detection and thrombosis prediction, 331–341
 successful maturation, predictors of, 1000–1012
 transposed basilic vein, vascular outcome and, 151–157

Ascorbic acid supplementation, effect on oxidative stress parameters in HD, 158–166

Aspirin
 for acute coronary syndromes in renal patients, 446–455
 kidney function changes in healthy men and, 234–244

Atherosclerosis
 carotid, in PD patients, 355–361
 in CRF, transesophageal echocardiography of, 277–285
 in end-stage renal disease, lipoprotein(a) and, 108–116
 malnutrition-inflammation complex syndrome in dialysis and, 864–881

with renal artery stenosis, medical management of, 851–857, 858–863

state of endothelium in hemodialysis, circulating endothelial cells and, 704–712

Atopy, interleukin-4-related gene polymorphisms and, 271–276

Atypical pneumonia, severe acute respiratory syndrome in hemodialysis patient, 1069–1074

Autologous stem cell transplantation, for LCDD with renal involvement, 1154–1163

Autosomal dominant polycystic kidney disease (ADPKD), nephrology core curriculum, 1305–1317

Autosomal recessive Alport's syndrome, as collagen type IV disease, 952–959

Autosomal recessive polycystic kidney disease (ARPKD), nephrology core curriculum, 1305–1317

AVF. *See* Arteriovenous fistula

BCAAs (branched-chain amino acids), in ESRD hemodialysis patients, 1212–1220

BCKAD (branched-chain keto acid dehydrogenase), hemodialysis effects on, 1212–1220

Benign familial hematuria, as collagen type IV disease, 952–959

Beta-blockers
 for hypertension treatment in incident HD and PD, 1260–1269
 utilization to reduce cardiovascular risk in dialysis patients, 1301–1304

Bicarbonate, albumin and creatinine serum levels in dialysis patients and, 1200–1211

Bicarbonate replacement fluid, and citrate anticoagulation for pediatric CVVH, 1248–1252

Bioavailability of ciprofloxacin, effects of calcium acetate and sevelamer on, 1253–1259

Bioimpedance spectroscopy, of large-artery structure and function in HD, 990–999

Bisphosphonate, PTH secretion in postmenopausal HD patients with secondary hyperparathyroidism, 1221–1227

Blindness, anterior ischemic optic neuropathy in pediatric CPD, 5:E19

Blood loss, anemia management in quotidian HD patients and, S1:18–23

Blood pressure
 anterior ischemic optic neuropathy in pediatric CPD, 5:E19
 chronic kidney disease risk and, S4:34–S4:41
 elevation. *See* Hypertension
 quotidian hemodialysis and, S1:13–17
 targeted kidney disease screening and, 22–35

Blood vessel prosthesis, in vivo validation of glucose pump test for access flow, 752–760

BMD (bone mineral density), intestinal calcium absorption in hypercalcemic stone-forming women and, 1177–1183

Body mass index (BMI)
 chronic kidney disease risk and, S4:34–S4:41
 health status of elderly, cystatin C and, 36–43
 KEEP program participants, S4:16–27, S4:28–33
 quotidian hemodialysis and, S1:30–35

in renal transplant recipients, exercise training effects on, 362–369

serum leptin in renal osteodystrophy and, 1036–1042

targeted kidney disease screening and, 22–35

Bone disease

- adynamic, S3:125–127
- assessment in chronic kidney disease, S3:57–62
- in chronic kidney disease, S3:29–44
- in kidney transplant recipient, S3:130–140

Bone histomorphometry, serum leptin in renal osteodystrophy and, 1036–1042

Bone marrow stem cells, for renal disease, 891–905

Bone marrow transplantation, renal tubular regeneration by bone marrow-derived cells after, 5:E20

Bone mineral density (BMD), intestinal calcium absorption in hypercalcic stone-forming women and, 1177–1183

Bone remodeling, after parathyroidectomy for secondary hyperparathyroidism, 729–738

Booster vaccination, natural hepatitis B immunity in long-term HD patients, 1193–1199

Bowel perforation, from peritoneoscopic PD catheter insertion, 1270–1274

Brain injury, starvation ketoacidosis and, 5:E22

Branched-chain amino acids (BCAAs), in ESRD hemodialysis patients, 1212–1220

Branched-chain keto acid dehydrogenase (BCKAD), hemodialysis effects on, 1212–1220

Cadaver kidney allocation, algorithm development for, 882–890

Calcineurin inhibitors, thrombotic microangiopathy after renal transplantation and, 1058–1068

Calcium

- adrenocorticotrophic hormone deficiency in long-term HD and, 2:E10
- hypocalcemia, in chronic kidney disease, S3:29–44
- intestinal absorption in idiopathic hypercalcemia, BMD in stone-forming women and, 1177–1183
- lanthanum carbonate effects on, 96–107
- metabolism, evaluation of, S3:52–57
- pamidronate for secondary hyperparathyroidism and, 1221–1227
- quotidian hemodialysis and, S1:24–29

Calcium acetate and sevelamer, bioavailability of ciprofloxacin and, 1253–1259

Calcium carbonate, vascular calcification in long-term HD and, 303–309

Calcium-channel blockers

- with ACE inhibitor, for nondiabetic nephropathy, 67–75
- for hypertension treatment in incident HD and peritoneal dialysis, 1260–1269

Calcium oxalate, nephrolithiasis in cystic fibrosis and, 1–11

Calcium-phosphorus product, K/DOQI Clinical Practice Guidelines, S3:77–84

Calcium × phosphate, quotidian hemodialysis and, S1:24–29

Cannulation, in quotidian hemodialysis, S1:56–60

CAPD. *See Continuous ambulatory peritoneal dialysis*

Caspase-3, in ESRD hemodialysis patients, 1212–1220

Cardiovascular disease

- circulating AGEs in renal failure, dietary glycotoxins and, 532–538
- CRP levels chronic kidney disease and, 44–52
- in dialysis patients, lipoprotein(a) and, 108–116
- in ESRD
- lipoprotein(a) and, 108–116
- prognostic value of cardiac markers for, 513–523
- hypertensive pregnancy and, 982–989
- malnutrition-inflammation complex syndrome in dialysis and, 864–881
- microalbuminuria as risk marker for, 596–598
- microalbuminuria testing methods in, 245–248
- progression of renal insufficiency in type 2 diabetes mellitus, 936–942
- risk factors
- in renal transplant patients, exercise training effects on, 362–369
- vascular calcification in long-term HD and, 303–309
- special studies, S5:141–150
- state of endothelium in HD, circulating endothelial cells and, 704–712

Carotid atherosclerosis, in PD patients, 355–361

Case mix, adapting Charlson Comorbidity Index for ESRD, 125–132

Cast nephropathy, Tamm-Horsfall glycoprotein and, 658–676

Catheter-related infections, triple- vs. dual-lumen catheters and, 315–324

Catheters

- insertion, in diagnostic and interventional nephrology program, 229–233
- mortality in elderly ESRD patients and, 1013–1019
- peritoneal dialysis, 1082–1096
- triple- vs. dual-lumen for hemodialysis and apheresis, 315–324

CD68, prognosis of MPGN type I renal dysfunction and, 1131–1138

Cell-mediated immunity, effect of hygiene and socioeconomic factors on, 575–581

Cellulose acetate high performance-210 hemodialyzer, levofloxacin removal, 342–349

CHANCE (Chronic Hemodialysis and New Cardiac Markers Evaluation), prognostic value of cardiac markers in ESRD, 513–523

Charlson Comorbidity Index, adapting for use in ESRD, 125–132

Chemotherapy, for LCCD with renal involvement, 1154–1163

Children

- on CPD, anterior ischemic optic neuropathy in, 5:E19
- CVVH with Normocarb replacement fluid and citrate anticoagulation, 1248–1252

in-center hemodialysis, ESRD Clinical Performance Measures Project 2002 Annual Report on, S2:48–56

with minimal change nephrotic syndrome, IL-4 gene polymorphisms in, 271–276

MPGN type I renal dysfunction prognosis, α -smooth muscle actin and, 1131–1138

renal transplant recipients, quality of life for, 431–445

renal tubular regeneration by bone marrow-derived cells after BMT, 5:E20
retransplantation after polyoma BK virus-associated allograft loss, 821–825
severe acidosis caused by starvation and stress, 5:E22
with steroid-resistant FSGS, prednisone and LDL apheresis for, 1121–1130

Chloride ion channels, nephrolithiasis in cystic fibrosis and, 1–11

Chloridorrhea, after small bowel transplant rejection, 1283–1286

Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study, Lp(a) in atherosclerotic cardiovascular disease, 108–116

Cholesterol in renal transplant recipients, exercise training effects on, 362–369

Chronic Hemodialysis and New Cardiac Markers Evaluation (CHANCE), prognostic value of cardiac markers in ESRD, 513–523

Chronic kidney disease (CKD)
analgesia in, 217–228
anemia in. *See Anemia*
aortic atherosclerosis in, 277–285
early detection of, 392–393
Healthy People 2010 objectives, S5:25–36
hospitalization frequency in, 972–981
incidence and outcomes, population-based study of, 677–684
K/DOQI Clinical Practice Guidelines. *See K/DOQI Clinical Practice Guidelines*
K/DOQI definition of, 623–625, 626–630
KEEP program participants, S4:16–27, S4:42–48
late referral to nephrologist, access to kidney transplantation and, 1043–1049
markers, position statement of NKF and NIDDK, 617–622
outcome, impact of nephrology referral on, 474–485
receipt of RRT, sociodemographic disparities and, 249–255
in renal hyperparathyroidism, percutaneous ethanol injection therapy for, 739–745
stage, in predicting seroconversion after HBV vaccination, 1184–1192
time to dialysis, predialysis psychoeducational intervention and coping styles, 693–703
USRDS annual report on, S5:37–46

Ciprofloxacin bioavailability, effects of calcium acetate and sevelamer on, 1253–1259

Circulating endothelial cells, endothelium in hemodialysis patients and, 704–712

Cirrhosis
hepatitis C virus and, 631–657
prediction of GFR in liver transplant candidates, 1169–1176

Citrate anticoagulation, with Normocarb replacement fluid for pediatric CVVH, 1248–1252

CKD. *See Chronic kidney disease*

Clinical performance measures, developing, based on K/DOQI Clinical Practice Guidelines, 806–812

Clinical trials. *See Randomized controlled trials; specific clinical trials*

Clopidogrel, for acute coronary syndromes in renal patients, 446–455

c-met, hereditary papillary renal cell carcinoma in renal allograft, 381–384

Cochrane Renal Group report, published and ongoing trials, 837–841

Cockcroft and Gault formula, prediction of GFR in liver transplant candidates, 1169–1176

Cohort studies of ARF, reasons for nonenrollment in, 507–512

Collagen type IV gene mutations in Alport's syndrome and benign familial hematuria, 952–959

Collapsing glomerulopathy, with membranous glomerulonephritis in native kidney biopsies, 591–595

Color Doppler ultrasound, vs. ultrasound dilution method or fistulography, 539–545

Congenital nephrotic syndrome, case report of, 1318–1323

Contamination, by HBV and HCV in dialysis setting, 546–550

Continuous ambulatory peritoneal dialysis (CAPD)
in Finland, cost analysis of, 1228–1238
long-term study of amino acid dialysate in, 173–183
rosiglitazone improvement of glucose metabolism in non-diabetic uremia, 774–780

Continuous peritoneal dialysis (CPD)
anterior ischemic optic neuropathy in children and, 5:E19
ultrafiltration volume measurement, by segmental bioimpedance analysis, 167–172

Continuous venovenous hemodialysis (CVVHD), vs. CVVH with Normocarb replacement fluid and citrate anticoagulation for children, 1248–1252

Continuous venovenous hemofiltration (CVVH)
with Normocarb replacement fluid and citrate anticoagulation, 1248–1252
single-dose ofloxacin pharmacokinetics in, 310–314

Coping styles, time to dialysis and, 693–703

Coronary heart disease. *See Cardiovascular disease*

Coronavirus, severe acute respiratory syndrome in hemodialysis patient, 1069–1074

Costs
analysis of renal replacement therapies in Finland, 1228–1238
comparison of conventional vs. home quotidian hemodialysis, S1:49–55
of dialysis in ESRD, 12–21

C-reactive protein (CRP)
albumin and creatinine independent association with, 1200–1211
carotid atherosclerosis in PD patients and, 355–361
in chronic kidney disease, 44–52
effect of malnutrition-inflammation complex on EPO hyperresponsiveness in maintenance HD, 761–773
maintenance HD patients with hypoalbuminemia, 286–294

muscle mass in long-term hemodialysis and, 295–302
urinary albumin excretion in type 2 diabetes mellitus and, 53–61

Creatinine, serum
chronic kidney disease incidence and outcomes and, 677–684
correlation with enPCR and CPR, 1200–1211

elevated, kidney disease screening for, 22–35
 prognosis for LCDD with renal involvement, 1154–1163
 progression of renal insufficiency in type 2 diabetes mellitus, 936–942
 vs. serum cystatin C in GFR estimating, 36–43

Creatinine clearance, prediction of GFR in liver transplant candidates, 1169–1176

Creatinine kinase, prognostic value in ESRD, 513–523

Crescentic glomerulonephritis
 ANCA-positive, associated with minocycline, 2:E9
 preexisting in renal allograft, 5:E23
 proteinuria, doxycycline effects on, 366–380

Cryoglobulinemia
 hepatitis C virus and, 631–657

Cryptoglobulinemia
 glomerulonephritis of, monoclonal gammopathy deposition and, 87–95

Crystals, in podocytes, 605–611

C-106T polymorphism of *AKR1B1*, in diabetic nephropathy, 943–951

CVVH. *See* Continuous venovenous hemofiltration

CVVHD, vs. CVVH with Normocarb replacement fluid and citrate anticoagulation for children, 1248–1252

Cyclophosphamide resistance in minimal change nephrotic syndrome, tacrolimus for, 5:E21

Cyclosporine, thrombotic microangiopathy after renal transplantation and, 1058–1068

Cystatin C, in elderly, 36–43

Cystic fibrosis, nephrolithiasis and, 1–11

Cystic fibrosis transmembrane conductance regulator, nephrolithiasis in cystic fibrosis and, 1–11

Cystic kidney diseases, nephrology core curriculum, 1305–1317

Cytochrome P-450, hepatic drug metabolism in kidney disease and, 906–925

Cytokines. *See also specific cytokines*
 effect of malnutrition-inflammation complex on EPO hypersensitivity in maintenance HD, 761–773
 in ESRD hemodialysis patients, 1212–1220
 in maintenance HD patients with hypoalbuminemia, 286–294

Daily hemodialysis
 adequacy of, S1:42–48
 anemia management, S1:18–23
 calcium and phosphate balance in, S1:24–29
 conversion to, comorbidity in ESRD and, 1020–1035
 nursing issues, S1:56–60
 nutritional status and, S1:30–35
 operating cost comparisons for, S1:49–55
 patient quality of life, S1:36–41
 technical considerations, S1:66–70
 volume control and blood pressure management in, S1:13–17

Demographics, receipt of RRT and, 249–255

Dense deposit disease
 early renal allograft dysfunction and, 207–211
 retinal abnormalities causing visual impairment, 2:E3

Depression, peritonitis in long-term PD and, 350–354

Diabetes mellitus
 AVF creation by nephrologists and, 1293–1300
 KEEP program patients, S4:16–27
 microalbuminuria testing methods, 245–248
 rapidly progressive irreversible renal failure with pancreatic insufficiency, 842–845
 state of endothelium in hemodialysis patients, circulating endothelial cells and, 704–712
 targeted kidney disease screening and, 22–35
 type 1, incidence of ESRD and survival after RRT, 117–124
 type 2, progression of renal insufficiency in, 936–942
 urinary albumin to osmolality ratio in predicting 24-hour urine albumin excretion, 685–692
 urinary NAG excretion, pentoxifylline and, 264–270

Diabetic nephropathy
 C-106T polymorphism of *AKR1B1* and, 943–951
 urinary albumin excretion, inflammatory parameters and, 53–61
 with vascular complications, ruboxistaurin for, 456–465
 in vitro closure time test for hemostasis assessment in, 746–751

Diagnostic and interventional nephrology program, development of, 229–233

Dialysate
 amino acid, long-term study in CAPD, 173–183
 calcium concentrations in, S3:98–102

Dialysis. *See also specific dialysis modalities*
 antihypertensive usage to reduce cardiovascular risk in, 1301–1304
 hepatitis B and C virus contamination, 546–550
 hepatitis C virus-related renal disease and, 631–657
 initiation, transplant evaluation before, 1050–1057
 long-term
 need for end-of-life care training in nephrology, 813–820
 xerostomia and xerophthalmia in end-stage renal disease, 722–728
 malnutrition-inflammation complex syndrome in, 864–881
 selection of modality, 1082–1096
 severe acute respiratory syndrome in, clinical presentation and outcome of, 1075–1081
 solutions, for peritoneal dialysis, 1082–1096
 in vitro closure time test for hemostasis assessment in, 746–751

Dialysis dose conversion, comorbidity of ESRD patients and, 1020–1035

Dialysis membrane composition, effect on erythrocyte response, 551–560

Dialysis prescription, for peritoneal dialysis, 1082–1096

Diarrhea
 chlordiarrhea after small bowel transplant rejection, 1283–1286
 watery, with hyperkalemia, 2:E5

Dietary glycotoxins, circulating advanced glycation end products in renal failure and, 532–538

Differentiation, of stem cells for kidney disease, 891–905

Diffuse alveolar hemorrhage in small-vessel vasculitis, plasmapheresis for, 1149–1153

Doxorubicin, for LCDD with renal involvement, 1154–1163

Doxycycline, effect on proteinuria in glomerulonephritis, 366–380

Drugs. *See also specific drugs*

- hepatic metabolism in kidney disease, 906–925
- toxicity, sirolimus-induced thrombotic microangiopathy after renal transplant, 202–206

Economic costs. *See Costs*

Elderly

- analgesia in end-stage renal disease, 217–228
- AVF creation by nephrologists and, 1293–1300
- chronic kidney disease incidence and outcomes and, 677–684
- health status, cystatin C and, 36–43
- survival, dialysis access type in ESRD patients and, 1013–1019

Embryonic stem cell research, ethical and legal issues, 891–905

End-of-life care, training in nephrology, need for, 813–820

Endothelial function, effect of ruboxistaurin in diabetic nephropathy, 456–465

Endothelial NO synthase gene polymorphism with basal peritoneal membrane function in uremia, 781–786

Endothelium, state in hemodialysis patients, circulating endothelial cells and, 704–712

Endovascular procedures, in diagnostic and interventional nephrology program, 229–233

End-stage renal disease (ESRD)

- analgesia in, 217–228
- anemia in. *See Anemia*
- anterior ischemic optic neuropathy in children on chronic peritoneal dialysis, 5:E19
- antihypertensive usage to reduce cardiovascular risk in dialysis patients, 1301–1304
- atherosclerotic cardiovascular disease, in dialysis patients, lipoprotein(a) and, 108–116
- comorbidity
 - Charlson Comorbidity Index prediction of, 125–132
 - conversion from conventional to short daily hemodialysis and, 1020–1035
- depression, peritonitis in long-term PD and, 350–354
- dialysis costs in, 12–21
- economic costs, S5:161–172
- hemodialysis patient with SARS and SLE, 1069–1074
- hospitalization frequency in, 972–981
- hyperphosphatemia, lanthanum carbonate for, 96–107
- hypertension treatment in incident HD and peritoneal dialysis, 1260–1269
- impact of nephrology referral on outcome, 474–485
- incidence, after renal replacement therapy for type 1 diabetes, 117–124
- international comparisons, S5:173–181
- kidney transplantation, S5:115–128
- late referral to nephrologist, access to kidney transplantation and, 1043–1049
- long-term peritoneal dialysis, gabapentin-induced hypoglycemia in, 6:E24
- maintenance hemodialysis, hypercoagulability in, 797–805
- markers of inflammation, proteolysis and apoptosis in, 1212–1220
- need for end-of-life care training in nephrology, 813–820
- outcomes, S5:103–114

patient characteristics, S5:61–74

pediatric, S5:129–140

peginterferon pharmacokinetics in, 631–657

prevalence and incidence, S5:47–60

prognostic value of cardiac markers in, 513–523

reduction of AGEs in long-term HD by on-line hemodialfiltration, 524–531

rehabilitation and quality of life, S5:151–160

renal replacement therapies in Finland, cost analysis of, 1228–1238

socioeconomic status effect on treatment, 249–255

treatment modalities, S5:75–86

xerostomia and xerophthalmia in, 722–728

ENOS gene polymorphism, with basal peritoneal membrane function in uremia, 781–786

enPCR (Equilibrated normalized protein catabolic rate), albumin and creatinine independent association with, 1200–1211

Epidemiology

- chronic kidney disease incidence and outcomes, population-based study of, 677–684
- of glomerulonephritis, effect of hygiene and socioeconomic factors, 575–581

Epidémiologie de l'Insuffisance Renale Chronique Terminale en Lorraine (EPIREL), impact of nephrology referral on ESRD outcome, 474–485

EPO. *See Erythropoietin*

Epoetin. *See Erythropoietin*

Epstein-Barr virus infection, adult-onset tubulointerstitial nephritis and uveitis and, 3:E11

Equilibrated normalized protein catabolic rate (enPCR), albumin and creatinine independent association with, 1200–1211

Equipment

- hepatitis B and C virus contamination in dialysis, 546–550
- for quotidian hemodialysis, S1:66–70

Erythrocyte aldose reductase, in Japanese patients with type 2 diabetes, 943–951

Erythropoiesis, hemodialysis membrane composition effect on erythrocyte response, 551–560

Erythropoietin (EPO). *See also Recombinant human erythropoietin*

- anemia management in quotidian hemodialysis, S1:18–23
- biocompatibility, hemodialysis membrane composition effect on erythrocyte response, 551–560

EPO-producing gastric carcinoma, in hemodialysis patient, 1:E1

- heme iron polypeptide in HD patients and, 325–330
- malnutrition-inflammation complex syndrome in dialysis and, 864–881

Escherichia coli, Tamm-Horsfall glycoprotein excretion and, 658–676

ESRD. *See End-stage renal disease*

ESRD Clinical Performance Measures Project 2002 Annual Report

- adult in-center HD patients, S2:19–38
- adult peritoneal dialysis, S2:39–48
- background and project methods, S2:11–18
- executive summary, S2:4–10
- pediatric in-center hemodialysis, S2:48–56

Estimated glomerular filtration rate, kidney disease screening, 22–35

Ethanol injection therapy, for HD patients with renal hyperparathyroidism, 739–745

Ethics
organ allocation for kidney transplantation, 882–890
of stem cell therapy for renal disease, 891–905

Ethnicity
chronic kidney disease risk, KEEP program participants and, S4:34–S4:41
quality of life in ESRD and, 713–721

Exercise training effects, on coronary risk factors in renal transplant patients, 362–369

Exocrine pancreatic insufficiency, in peritoneal dialysis patients, 787–796

Extracellular fluid volume
quotidian hemodialysis and, S1:13–17
ratio to intracellular fluid, large-artery derangement in HD and, 990–999

Familial juvenile hyperuricemic nephropathy, Tamm-Horsfall glycoprotein and, 658–676

Familial renal hypouricemia, with exercise-induced ARF, 1287–1292

Ferritin, serum
heme iron polypeptide in HD patients and, 325–330
in vitro oxidative effects of ascorbic acid in uremia and, 158–166

Finland, cost analysis of renal replacement therapies in, 1228–1238

Fistula, mortality in elderly ESRD patients and, 1013–1019

Fistulography, vs. color Doppler ultrasound or ultrasound dilation method, 539–545

Flushing, cyclosporine-induced in minimal change nephrotic syndrome, 5:E21

Focal segmental glomerulonephritis, idiopathic, with membranous glomerulonephritis in native kidney biopsies, 591–595

Focal segmental glomerulosclerosis (FSGS)
and hyalinosis with lymphoproliferative disorders, 1097–1101
incidence in children, 1107–1113
steroid-dependent, mycophenolate mofetil and prednisolone for, 1114–1120
steroid-resistant, prednisone and LDL apheresis for, 1121–1130

Follow-up study, of healthy subjects with microalbuminuria, all-cause mortality and, 466–473

FSGS. *See* Focal segmental glomerulosclerosis

Furosemide, for Gitelman's syndrome with Sjogren's syndrome, 586–590

Gabapentin-induced hypoglycemia, in long-term peritoneal dialysis patient, 6:E24

Gastric carcinoma, EPO-producing in hemodialysis patient, 1:E1

Gastrointestinal dysfunction, in peritoneal dialysis patients, 787–796

Gender
chronic kidney disease risk and, S4:34–S4:41
quality of life in ESRD and, 713–721

Gene polymorphisms
in children with minimal change nephrotic syndrome, 271–276

ENOS, with basal peritoneal membrane function in uremia, 781–786

Genetic association, matrix metalloproteinase 9 gene in ESRD, 133–142

GFR. *See* Glomerular filtration rate

Gitelman's syndrome
NCCT gene mutations in Korean patient, 6:E26
with Sjogren's syndrome presenting with muscular paralysis, 586–590

Glomerular filtration rate (GFR)
analgesia in healthy men and, 234–244
chronic kidney disease and, S4:42–S4:48
C-reactive protein levels chronic kidney disease and, 44–52
in elderly, cystatin C as marker for, 36–43
estimated, for kidney disease screening, 22–35
position statement of NKF and NIDDK, 617–622
prediction in liver transplant candidates, 1169–1176
resistin blood levels in renal disease and, 62–66

Glomerulonephritis. *See also* Crescentic glomerulonephritis; Membranoproliferative glomerulonephritis
AGBM antibody-induced, with periglomerular granulomatous reaction and eosinophilic infiltration, 3:E16
ANCA-positive, recurrence after kidney transplantation, 4:E18
hepatitis C virus and, 631–657
hygiene hypothesis of, 575–581
proteinuria, doxycycline effects on, 366–380
Glucocorticoids, cystatin C increase in elderly and, 36–43

Glucose, starvation ketoacidosis and, 5:E22

Glucose pump tests, for access flow measurement, in vivo validation of, 752–760

Glucose tolerance, rosiglitazone effect in nondiabetic uremic patients on CAPD, 774–780

Glycosyl phosphatidylinositol anchored proteins, Tamm-Horsfall glycoprotein excretion and, 658–676

Goodpasture's syndrome, dual pattern of immunofluorescence positivity, 419–426

Growth factor urinary excretion, MGN clinical course and, 1139–1148

Haplotype, erythrocyte aldose reductase in type 2 diabetes and, 943–951

HBV. *See* Hepatitis B virus

HCV. *See* Hepatitis C virus

HD. *See* Hemodialysis

HDL in renal transplant recipients, exercise training effects on, 362–369

Health care resources, utilization in advancing chronic kidney disease, 972–981

Health insurance, access to care and, 249–255

Health-related quality of life. *See* Quality of life

Health Utilities Index, quality of life on quotidian hemodialysis, S1:36–41

Healthy People 2010, chronic kidney disease objectives, S5: 25–36

Heart Outcomes and Prevention Evaluation (HOPE), results of, 936–942

Hematocrit, heme iron polypeptide in HD patients and, 325–330

Hematuria, targeted kidney disease screening and, 22–35

Heme iron polypeptide, as replacement of IV iron therapy in HD patients, 325–330

Hemodialfiltration, on-line, reduction of AGEs in long-term HD, 524–531

Hemodialysis (HD)

- access. *See* Vascular access
- acquired reactive perforating collagenosis, allopurinol for, 3:E12
- ascorbic acid effect on in vitro oxidative stress parameters, 158–166
- conventional, conversion to daily HD, comorbidity in ESRD and, 1020–1035
- cost analysis in Finland, 1228–1238
- daily. *See* Daily hemodialysis
- effects of CRP, enPCR and serum bicarbonate on creatinine and albumin levels, 1200–1211
- effects on ubiquitin-proteasome and BCKAD pathways, 1212–1220
- EPO-producing gastric carcinoma in, 1:E1
- in ESRD, costs of, 12–21
- for HCV-positive patients, effect on viremia and IFN- α levels, 143–150
- home
 - patient monitoring, S1:61–65
 - technical considerations, S1:66–70
- hypertension treatment in, 1260–1269
- in-center, ESRD Clinical Performance Measures Project 2002 Annual Report on
 - adult, S2:19–38
 - pediatric, S2:48–56
- initial access type, mortality outcomes in elderly ESRD patients, 1013–1019
- large-artery derangement in, ECF-ICF ratio and, 990–999
- levofloxacin clearance in ESRD, 342–349
- long-term
 - adrenocorticotropic hormone deficiency presenting with hypercalcemia in, 2:E10
 - vascular calcification, serum osteoprotegerin and, 303–309
- maintenance
 - in ESRD, hypercoagulability and, 797–805
 - hypoalbuminemia linked with inflammation and oxidative stress in, 286–294
- morbidity/mortality, S1:5–12
- nocturnal. *See* Nocturnal hemodialysis
- outcome
 - impact of nephrology referral for ESRD, 474–485
 - transposed basilic vein arteriovenous fistula and, 151–157
 - pain, 1239–1247
- predictors of successful AVF maturation, 1000–1012
- prognostic value of cardiac markers in ESRD, 513–523
- PTH secretion in postmenopausal women with secondary hyperparathyroidism, pamidronate effects on, 1221–1227
- quality of life in ESRD, symptoms, spiritual beliefs, psychosocial factors and ethnicity, 713–721
- quotidian, S1:5–12

renal osteodystrophy, serum leptin in, 1036–1042

severe acute respiratory syndrome in, 1069–1074

state of endothelium, circulating endothelial cells and, 704–712

triple- vs. dual-lumen catheters for, 315–324

ultrasound dilution access blood flow for AVFs, 331–341

in vitro closure time test for hemostasis assessment in, 746–751

Hemodialysis membrane, in vitro performance after repeated processing, 561–566

Hemoglobin

- hemodialysis membrane composition effect on erythrocyte response, 551–560
- quality of life in ESRD and, 713–721
- targeted kidney disease screening and, 22–35

Hemolytic uremic syndrome, thrombotic microangiopathy after renal transplantation and, 1058–1068

Heparin, for acute coronary syndromes in renal patients, 446–455

Hepatitis B surface antigen, contamination in dialysis setting, 546–550

Hepatitis B virus (HBV)

- contamination dialysis setting, 546–550
- evaluation in renal allograft recipients, 193–201
- natural immunity in long-term HD patients, 1193–1199
- vaccination before dialysis, stage of CKD in predicting seroconversion, 1184–1192

Hepatitis C virus (HCV)

- contamination dialysis setting, 546–550
- effect of hemodialysis on viremia and IFN- α levels, 143–150
- evaluation in renal allograft recipients, 193–201
- long-term ribavirin therapy for renal transplant patients, 184–192
- renal disease and, 631–657

Hereditary nephritis, nephrology core curriculum, 1305–1317

Hereditary papillary renal cell carcinoma, in renal allograft, 381–384

High-density lipoprotein in renal transplant recipients, exercise training effects on, 362–369

Hinge glycoproteins, in IgA nephropathy, 486–496

HIV-associated nephropathy, in African-American male, 6:E25

Home hemodialysis

- patient monitoring, S1:61–65
- technical considerations, S1:66–70

Homocysteine

- carotid atherosclerosis in PD patients and, 355–361
- quotidian hemodialysis and, S1:13–17

HOPE (Heart Outcomes and Prevention Evaluation), results of, 936–942

Hospitalization

- during advancing chronic kidney disease, 972–981
- ESRD, USRDS annual report on, S5:103–114

Hospital resource utilization, dialysis costs in ESRD and, 12–21

Human leukocyte antibodies, organ allocation for kidney transplantation, 882–890

Hyaluronate, evaluation of HBV- and HCV-infected renal allografts, 193–201

Hygiene hypothesis, of glomerulonephritis, 575–581

Hypercalcemia, adrenocorticotrophic hormone deficiency in long-term HD, 2:E10

Hypercalciuria, idiopathic, intestinal calcium absorption–bone mineral density relationship in stone-forming women, 1177–1183

Hypercholesterolemia, aortic atherosclerosis in chronic renal failure, 277–285

Hypercoagulability, in ESRD patients on maintenance hemodialysis, 797–805

Hypoglycemia, effect of protein kinase C β inhibition on, 456–465

Hyperinsulinemia, gabapentin-induced hypoglycemia in long-term peritoneal dialysis, 6:E24

Hyperkalemia, with concomitant watery diarrhea, 2:E5

Hyperoxaluria, nephrolithiasis in cystic fibrosis and, 1–11

Hyperparathyroid and mixed bone disease, K/DOQI Clinical Practice Guidelines, S3:123–124

Hyperparathyroidism, secondary

- bone remodeling changes after parathyroidectomy, 729–738
- in chronic kidney disease, S3:29–44
- in postmenopausal HD patients, pamidronate effects on PTH secretion, 1221–1227
- renal HD patients, percutaneous ethanol injection therapy for, 739–745

Hyperphosphatemia

- in chronic kidney disease, S3:29–44
- in end-stage renal disease, lanthanum carbonate for, 96–107

Hypertension

- aortic atherosclerosis in chronic renal failure, 277–285
- chronic kidney disease risk and, S4:34–S4:41
- health status of elderly, cystatin C and, 36–43
- KEEP program patients, S4:16–27
- in pregnancy, cardiovascular disease and thromboembolic events associated with, 982–989
- progression of renal insufficiency in type 2 diabetes mellitus, 936–942
- state of endothelium in HD patients, circulating endothelial cells and, 704–712
- targeted kidney disease screening and, 22–35
- treatment in incident HD and peritoneal dialysis, 1260–1269

Hyperuricosuria, nephrolithiasis in cystic fibrosis and, 1–11

Hypoalbuminemia

- chronic kidney disease and, 256–263
- inflammation and oxidative stress in maintenance HD patients and, 286–294

Hypocalcemia, in chronic kidney disease, S3:29–44

Hypochloremia, after small bowel transplant rejection-related diarrhea, 1283–1286

Hypocitraturia, nephrolithiasis in cystic fibrosis and, 1–11

Hypoglycemia, gabapentin-induced, in long-term peritoneal dialysis patient, 6:E24

Hypomagnesemia, in atypical Gitelman's syndrome, 6:E26

Hypotension, anterior ischemic optic neuropathy in children on chronic peritoneal dialysis, 5:E19

Hypovolemia, anterior ischemic optic neuropathy in children on chronic peritoneal dialysis, 5:E19

Idiopathic membranoproliferative glomerulonephritis, clinical course, VEGF excretion and, 1139–1148

IgA1, produced by tonsillar lymphocytes in IgA nephropathy, 486–496

IL-4 gene polymorphisms, in children with minimal change nephrotic syndrome, 271–276

Imaging. *See also specific imaging methods*

- of medullary cystic kidney disease with MRI, 1:E2
- nephrology core curriculum, 601–604

Immune complex syndromes, hepatitis C virus and, 631–657

Immunoglobulin A nephropathy

- nuclear factor κ -B detection in, 76–86
- resistin blood level increase in glomerulonephritis, 62–66
- tonsillar lymphocytes IgA1 O-glycan structure in, 486–496

Immunosuppression

- sirolimus-induced thrombotic microangiopathy after renal transplant, 202–206
- thrombotic microangiopathy after renal transplantation and, 1058–1068

Inflammation

- albumin and creatinine independent association with, 1200–1211
- chronic kidney disease and, 256–263
- erythropoietin hyporesponsiveness in maintenance HD and, 761–773
- in maintenance HD patients with hypoalbuminemia, 286–294
- markers in ESRD hemodialysis patients, 1212–1220
- serum markers. *See also* C-reactive protein; Interleukin-6
- chronic kidney disease and, 256–263
- and muscle mass in long-term hemodialysis, 295–302
- urinary albumin in type 2 diabetes and, 53–61

Inherited kidney diseases, nephrology core curriculum, 1305–1317

Insulin resistance

- in renal disease, resistin and, 62–66
- rosiglitazone in nondiabetic uremic patients on CAPD, 774–780

Intact parathyroid hormone, bone management in quotidian hemodialysis, S1:24–29

Interferon- α

- in HCV-positive hemodialysis patients, 143–150
- for hepatitis C virus-related renal disease, 631–657

Interleukin-1, in ESRD hemodialysis patients, 1212–1220

Interleukin-6

- effect of malnutrition-inflammation complex on EPO hyporesponsiveness in maintenance HD, 761–773
- in ESRD hemodialysis patients, 1212–1220
- in maintenance HD patients with hypoalbuminemia, 286–294
- muscle mass in long-term hemodialysis and, 295–302

Interstitial nephritis, Tamm-Horsfall glycoprotein and, 658–676

Interventional nephrology program

- development of, 229–233
- peritoneoscopic PD catheter insertion, bowel perforation from, 1270–1274
- as work in progress, 388–391

Intradialytic weight gain, quotidian hemodialysis and, S1: 13–17

Intravascular lymphoma, diagnosed by percutaneous kidney biopsy, 960–971

In vitro closure time test, for hemostasis assessment in HD patients, 746–751

Iothalamate clearance, prediction of GFR in liver transplant candidates, 1169–1176

Iron

- dialysis membrane composition effect on erythrocyte response, 551–560
- hem iron polypeptide in HD patients, 325–330

Ischemic renal injury, atherosclerotic renal artery stenosis and, 858–863

Japanese patients

- with minimal change nephrotic syndrome, IL-4-related gene polymorphisms in, 271–276
- with type 2 diabetes, erythrocyte aldose reductase in, 943–951

Kaplan-Meier survival curves, vs. Charlson Comorbidity Index for predicting survival in ESRD, 125–132

K/DOQI Clinical Practice Guidelines

- adynamic bone disease, S3:125–127
- aluminum overload and toxicity in CKD, S3:108–116
- background, S3:29–44
- bone disease in kidney transplant recipient, S3:130–143
- chronic kidney disease
 - for dietary phosphorus restrictions, S3:63–70
 - phosphate binder usage, S3:70–77
- clinical performance measures based on, 806–812
- definition of chronic kidney disease, 623–625, 626–630
- dialysate calcium concentrations, S3:98–102
- evaluation of calcium and phosphorus metabolism in chronic kidney disease, S3:52–57
- hyperparathyroid and mixed bone disease, S3:123–124
- metabolic acidosis, S3:129–130
- methods for analysis of literature, S3:45–51
- β 2-microglobulin amyloidosis, S3:102–108
- osteomalacia, S3:124–125
- parathyroidectomy in CKD, S3:127–129
- phosphorus evaluation in chronic kidney disease, S3: 62–63
- statements, S3:12–28
- targeted kidney disease screening and, 22–35
- treatment algorithm for aluminum overload, S3:116–122
- vitamin D insufficiency/deficiency treatment, S3:84–89
- Vitamin D therapy in dialysis patients, S3:92–98
- work group members, biographical sketches, S3:144–147

KEEP program

- analytical methods, S4:57–60
- anemia and chronic kidney disease, S4:49–S4:56
- demographics, S4:8–15
- early detection of kidney disease in community setting, 22–35
- overview, S4:3–15
- patient characteristics, S4:16–27

Ketoacidosis, caused by starvation and stress, 5:E22

Kidney, donor allocation, 882–890

Kidney Disease Outcomes Quality Initiative. *See* K/DOQI Clinical Practice Guidelines

Kidney Early Evaluation Program. *See* KEEP program

Kidney function

- effects of analgesic usage in healthy men, 234–244
- levels, in predicting seroconversion after HBV immunization, 1184–1192

Kidney stones, cystic fibrosis and, 1–11

Kidney transplantation

- access, late referral to nephrologist and, 1043–1049
- allograft. *See* Allograft, renal
- for amyloidosis, long-term outcome of, 370–375
- cadaveric, de novo systemic lupus erythematosus after, 3:E15
- correction of hypercoagulability in end-stage renal disease, 797–805
- donor kidney allocation, 882–890
- for ESRD, S5:115–128
- evaluation, timing of, 1050–1057
- in Finland, cost analysis of, 1228–1238
- HBV- and HCV-infected allograft, evaluation of, 193–201
- for HCV-positive patients, long-term ribavirin therapy for, 184–192
- for hepatitis C virus-related renal disease, 631–657
- hereditary papillary renal cell carcinoma in renal allograft, 381–384
- impact of referral on ESRD outcome, 474–485
- preemptive
 - residual renal function effects on graft and patient survival rates, 1275–1282
 - vs. nonpreemptive, 1050–1057
- quality of life after, 431–445
- recipients
 - bone disease in, S3:130–143
 - coronary risk factors, exercise training effects on, 362–369
 - sirolimus-induced thrombotic microangiopathy in, 202–206
- recurrence of ANCA-positive glomerulonephritis after, 4:E18
- retransplantation after polyoma BK virus-associated allograft loss, 821–825

Korean man, NCCT gene mutations in atypical Gitelman's syndrome, 6:E26

Kt/V, quotidian hemodialysis and, S1:42–48

Laboratory survey, of microalbuminuria testing methods, 245–248

Lacrimal secretion, in end-stage renal disease, 722–728

Lactate dehydrogenase, effect of malnutrition-inflammation complex on EPO hyporesponsiveness in maintenance HD, 761–773

Lamellar osteoid, after parathyroidectomy for secondary hyperparathyroidism, 729–738

Lanthanum carbonate, safety/efficacy of, 96–107

Large-artery derangement, extracellular fluid-to-intracellular fluid volume ratio and, 990–999

LCDD. *See* Light chain deposition disease

LDH, effect of malnutrition-inflammation complex on EPO hyporesponsiveness in maintenance HD, 761–773

LDL apheresis, for steroid-resistant focal segmental glomerulosclerosis, 1121–1130

Lead-time bias, residual renal function in preemptive kidney transplantation and, 1275–1282

Legal aspects, of stem cell therapy for renal disease, 891–905

Leptin, in dialysis renal osteodystrophy, 1036–1042

Leukocytosis, chronic kidney disease and, 256–263

Levofloxacin, pharmacokinetics in ESRD, 342–349

LHCDD, monoclonal gammopathy deposition and, 87–95

LIFE (Losartan Intervention for Endpoint reduction), anti-hypertensive usage to reduce cardiovascular risk in dialysis patients, 1301–1304

Light and heavy chain deposition disease (LHCDD), monoclonal gammopathy deposition and, 87–95

Light chain amyloidosis, monoclonal gammopathy deposition and, 87–95

Light chain cast nephropathy, monoclonal gammopathy deposition and, 87–95

Light chain deposition disease (LCDD) monoclonal gammopathy deposition and, 87–95 with renal involvement, 1154–1163

Linkage analysis, in Alport's syndrome and benign familial hematuria, 952–959

Lipids, aortic atherosclerosis in chronic renal failure, 277–285

Lipoprotein(a)

- atherosclerotic cardiovascular disease in dialysis patients and, 108–116
- carotid atherosclerosis in PD patients and, 355–361

Lipoprotein glomerulopathy, with psoriasis vulgaris, with apolipoprotein E3/3, 3:E14

Liposomal amphotericin B, for mucormycosis peritonitis during long-term peritoneal dialysis, 3:E13

Liver enzymes, evaluation of HBV- and HCV-infected renal allografts, 193–201

Liver fibrosis

- evaluation of HBV- and HCV-infected renal allografts, 193–201
- HCV-positive renal transplant patients, long-term ribavirin therapy for, 184–192

Liver histology, HCV-positive renal transplant patients, long-term ribavirin therapy for, 184–192

London Daily/Nocturnal Hemodialysis Study, patient monitoring in, S1:61–65

Losartan Intervention for Endpoint reduction (LIFE), anti-hypertensive usage to reduce cardiovascular risk in dialysis patients, 1301–1304

Low-density lipoprotein apheresis, for steroid-resistant focal segmental glomerulosclerosis, 1121–1130

Lymphomas, diagnosed by percutaneous kidney biopsy, 960–971

Magnetic resonance imaging, of medullary cystic kidney disease, 1:E2

Maintenance hemodialysis

- in ESRD, hypercoagulability and, 797–805
- hypalbuminemia linked with inflammation and oxidative stress in, 286–294

Malacoplakia, positron emission tomography of, 3:E17

Malnutrition

- of CAPD patients, long-term study of amino acid dialysate in, 173–183
- with inflammation in dialysis, 864–881
- in long-term hemodialysis, inflammatory mediators and, 295–302
- peritoneal membrane abnormalities and, 787–796

Malnutrition-inflammation complex syndrome

- in dialysis, 864–881
- effect on EPO hyporesponsiveness in maintenance HD, 761–773

Mass screening methods, for microalbuminuria testing, 245–248

Matrix metalloproteinase 9 gene, in ESRD, 133–142

MDRD. *See* Modification of Diet in Renal Disease

Medical education

- core nephrology curriculum. *See* Nephrology core curriculum
- need for end-of-life care training in nephrology, 813–820

Medical Outcomes Survey 36-Item Short Form, quality of life on quotidian hemodialysis, S1:36–41

Medullary cystic kidney disease

- magnetic resonance imaging of, 1:E2
- nephrology core curriculum, 1305–1317
- type 2, Tamm-Horsfall glycoprotein and, 658–676

MELD (Model for End-Stage Liver Disease), prediction of GFR in liver transplant candidates, 1169–1176

Membranoproliferative glomerulonephritis (MPGN)

- clinical course, VEGF excretion and, 1139–1148
- dense deposit disease
- early renal allograft dysfunction and, 207–211
- retinal abnormalities causing visual impairment, 2:E3
- hepatitis C virus and, 631–657
- hygiene hypothesis of, 575–581
- type I, renal dysfunction prognosis, a-smooth muscle actin and, 1131–1138
- type II, early renal allograft dysfunction and, 207–211

Membranous glomerulopathy

- with collapsing glomerulopathy in native kidney biopsies, 591–595
- dual pattern of immunofluorescence positivity, 419–426

Men

- carotid atherosclerosis in PD patients and, 355–361
- chronic kidney disease risk and, S4:34–S4:41
- quality of life in ESRD and, 713–721

Mesangial proliferative glomerulonephritis

- hygiene hypothesis of, 575–581
- nuclear factor κ-B expression in, 76–86

Mesangiocapillary glomerulonephritis type II, retinal abnormalities causing visual impairment, 2:E3

Metabolic acidosis, K/DOQI Clinical Practice Guidelines, S3:129–130

Metabolic alkalosis, hypochloremic, after small bowel transplant rejection-related diarrhea, 1283–1286

Metalloproteinase inhibitor, proteinuria in crescentic glomerulonephritis and, 366–380

MGUS (monoclonal gammopathy of undetermined significance), renal disease and, 87–95

Microalbuminuria

- all-cause mortality and, 466–473
- as cardiovascular risk marker, 596–598

current testing methods, 245–248
 prediction in diabetes mellitus, urinary albumin to osmolality ratio and, 685–692
 progression of renal insufficiency in type 2 diabetes, 936–942
 targeted kidney disease screening and, 22–35
 in type 2 diabetes mellitus, 53–61

Microangiopathy, sirolimus-induced thrombotic, after renal transplant, 202–206

β 2-Microglobulin amyloidosis, K/DOQI Clinical Practice Guidelines, S3:102–108

Microscopic polyangiitis, subarachnoid hemorrhages in, 582–585

Minimal change nephrotic syndrome
 in children, 271–276, 1107–1113
 IL-4-related gene polymorphisms in, 271–276
 mycophenolate mofetil and prednisolone for, 1114–1120
 nuclear factor κ -B expression in, 76–86

Minocycline, ANCA-positive crescentic glomerulonephritis and, E9

Model for End-Stage Liver Disease (MELD), prediction of GFR in liver transplant candidates, 1169–1176

Modification of Diet in Renal Disease (MDRD)
 C-reactive protein in chronic kidney disease and, 44–52
 prediction of GFR in liver transplant candidates, 1169–1176

Monitoring of patient, during daily and nocturnal hemodialysis, S1:61–65

Monoclonal gammopathy
 with nephrotic syndrome, 1097–1101
 renal disease and, 87–95

Monoclonal light chain deposition, intracellular accumulation, 605–611

Montana, microalbuminuria testing in, 245–248

Morbidity in ESRD, USRDS annual report on, S5:103–114

Mortality
 AVF creation by nephrologists and, 1293–1300
 dialysis access type in ESRD patients and, 1013–1019
 hypertension treatment in incident HD and peritoneal dialysis, 1260–1269
 microalbuminuria and, 466–473
 from renal artery stent placement, predictive value of renal insufficiency in, 926–935

MPGN. See Membranoproliferative glomerulonephritis

Mucormycosis peritonitis, on long-term PD, liposomal amphotericin B for, 3:E13

Multiorgan failure, during sickle cell crisis in sickle/ β -thalassemia, E4

Multiple myeloma, with crystals in podocytes, 605–611

Multiple organ failure, single-dose ofloxacin pharmacokinetics in CVVH, 310–314

Multivariate analysis, of health status in elderly, 36–43

Muscle mass
 creatinine and albumin levels in dialysis patients and, 1200–1211
 in long-term hemodialysis, inflammatory mediators and, 295–302

Muscular paralysis, Sjogren's syndrome with Gitelman's syndrome and, 586–590

Mutations
 in Alport's syndrome and benign familial hematuria, 952–959
 Na-CL cotransporter gene in Gitelman's syndrome, 6:E26

Mycophenolate mofetil, with prednisolone for steroid-dependent nephrotic syndrome, 1114–1120

Myeloma, with focal segmental glomerulosclerosis, 1097–1101

Myeloma nephropathy, Tamm-Horsfall glycoprotein and, 658–676

Myocardial infarction, hypertensive pregnancy and, 982–989

Na⁺/H⁺ exchanger isoform 3 protein (NHE3), as marker for tubular injury in ARF, 497–506

Narcotic analgesics, in end-stage renal disease, 217–228

National Health and Nutrition Examination Surveys (NHANES)
 second
 inflammatory markers, CKD and, 256–263
 receipt of RRT, sociodemographic disparities in, 249–255
 third
 chronic kidney disease risk, S4:34–S4:41
 demographics of KEEP program, S4:8–15
 KEEP program participant characteristics, S4:16–27

National Kidney Disease Education Program, early detection of chronic kidney disease, 392–393

National Kidney Foundation Kidney Early Evaluation Program. See also KEEP program
 annual data report, S4:5–60

Natural immunity, HBV, in long-term HD patients, 1193–1199

NCCT gene mutations, in Korean Gitelman's syndrome patient, 6:E26

Neonate, nephrotic syndrome in, 1318–1323

Nephrin, in congenital nephrotic syndrome, 1318–1323

Nephrocalcinosis, in cystic fibrosis, 1–11

Nephrolithiasis, cystic fibrosis and, 1–11

Nephrologists, AVF creation, 1293–1300

Nephrology, need for end-of-life care training in, 813–820

Nephrology core curriculum
 cystic and inherited kidney diseases, 1305–1317
 imaging, 601–604
 as outline for nephrology trainees, 215–216, 395–418
 for peritoneal dialysis, 1082–1096
 renal biopsy, 826–836

Nephropathy, nondiabetic, effect of ACE inhibitors on, 67–75

Nephrosclerosis, progression of renal insufficiency in type 2 diabetes mellitus, 936–942

Nephrotic syndrome
 HIV-associated, in African-American male, 6:E25
 with monoclonal gammopathy, 1097–1101
 non-minimal change, in children, 1107–1113
 in renal lymphoma, diagnosis by percutaneous kidney biopsy, 960–971

NHANES. See National Health and Nutrition Examination Surveys

NHE3 protein, as novel urinary markers for early ARF, 599–600

NKF-K/DOQI Clinical Practice Guidelines. *See* K/DOQI Clinical Practice Guidelines

Nocturnal hemodialysis

- adequacy of, S1:42–48
- anemia management, S1:18–23
- calcium and phosphate balance in, S1:24–29
- London Daily/Nocturnal Hemodialysis Study, S1:5–12
- nursing issues, S1:56–60
- nutritional status and, S1:30–35
- operating cost comparisons for, S1:49–55
- patient monitoring, S1:61–65
- patient quality of life, S1:36–41
- technical considerations, S1:66–70
- volume control and blood pressure management in, S1:13–17

Nondiabetic patients with microalbuminuria, all-cause mortality and, 466–473

Nonhypertensive patients with microalbuminuria, all-cause mortality and, 466–473

Nonproliferative glomerulonephritis, nuclear factor κ-B expression in, 76–86

Nonsteroidal anti-inflammatory drugs (NSAIDs)

- in end-stage renal disease, 217–228
- renal disease in postphenacetin era and, 385–387

Nord-Trøndelag Health Study (HUNT), microalbuminuria, all-cause mortality and, 466–473

Normocarb replacement fluid, and citrate anticoagulation for pediatric CVVH, 1248–1252

NSAIDs. *See* Nonsteroidal anti-inflammatory drugs

Nuclear factor κ-B, detection in IgA nephropathy, 76–86

Nursing issues, in quotidian hemodialysis, S1:56–60

Nutrient protein equivalent of total nitrogen appearance, quotidian hemodialysis and, S1:30–35

Nutrineal, long-term study in CAPD, 173–183

Nutrition

- albumin and creatinine independent association with, 1200–1211
- dietary glycoxins, circulating AGEs in renal failure and, 532–538
- quotidian hemodialysis and, S1:30–35

Obesity

- chronic kidney disease risk and, S4:34–S4:41
- KEEP program participants, S4:16–S4:27, S4:28–S4:33

Ofoxacin, pharmacokinetics during CVVH, 310–314

O-Glycan structure, of IgA1 produced by tonsillar lymphocytes in IgA nephrology, 486–496

On-line hemodialfiltration, reduction of advanced glycation end products in long-term HD, 524–531

Operating costs, comparison of conventional vs. home quotidian hemodialysis, S1:49–55

Opioids, for pain in hemodialysis, 1239–1247

Organ allocation, for kidney transplantation, 882–890

Osteoblasts, after parathyroidectomy for secondary hyperparathyroidism, 729–738

Osteoclasts, after parathyroidectomy for secondary hyperparathyroidism, 729–738

Osteomalacia, K/DOQI Clinical Practice Guidelines, S3:124–125

Osteoporosis, intestinal calcium absorption in hypercalcic stone-forming women and, 1177–1183

Osteoprotegerin

- progression of vascular calcification in long-term HD and, 303–309
- serum leptin in renal osteodystrophy and, 1036–1042

Outcome

- conversion from conventional to daily HD for ESRD patients, 1020–1035
- dialysis costs in ESRD and, 12–21
- of dialysis with malnutrition-inflammation complex, 864–881
- ESRD, USRDS annual report on, S5:103–114
- long-term of kidney transplantation for amyloidosis, 370–375
- of severe acute respiratory syndrome in dialysis, 1075–1081

Oxalate nephropathy

- nephrolithiasis in cystic fibrosis, 1–11
- rapidly progressive renal failure with pancreatic insufficiency, 842–845

Oxalobacter formigenes, nephrolithiasis in cystic fibrosis and, 1–11

Oxaluria, nephrolithiasis in cystic fibrosis and, 1–11

Oxidative stress

- during hemodialysis, ascorbic acid effects on, 158–166
- in maintenance HD patients with hypoalbuminemia, 286–294

Pain

- in hemodialysis patients, 1239–1247
- quality of life in ESRD and, 713–721

Pamidronate, PTH secretion in postmenopausal HD patients with secondary hyperparathyroidism, 1221–1227

Pancreas transplantation, quality of life after, 431–445

Pancreatic function

- insufficient, with rapidly progressive renal failure, 842–845
- in peritoneal dialysis patients, 787–796

Parathyroidectomy

- in CKD, K/DOQI Clinical Practice Guidelines, S3:127–129
- for secondary hyperparathyroidism, bone remodeling changes after, 729–738
- vs. percutaneous ethanol injection therapy for renal hyperparathyroidism in HD patients, 739–745

Parathyroid hormone (PTH). *See also* Hyperparathyroidism

- lanthanum carbonate effects on, 96–107
- secretion, pamidronate effects in postmenopausal HD patients with secondary hyperparathyroidism, 1221–1227
- serum leptin in renal osteodystrophy and, 1036–1042

Patient education, time to dialysis and, 693–703

PD. *See* Peritoneal dialysis

Pediatric patients. *See* Children

Peginterferon, pharmacokinetics in ESRD, 631–657

Pentoxifylline, urinary NAG in type 2 diabetes and, 264–270

Percutaneous angioplasty, of atherosclerotic renal artery stenosis, 851–857, 858–863

Percutaneous ethanol injection therapy, for HD patients with renal hyperparathyroidism, 739–745

Percutaneous renal artery angioplasty, for atherosclerotic renal artery stenosis, 851–857

Peritoneal dialysis (PD). *See also specific peritoneal dialysis modalities*

- adequacy of, 1082–1096
- adult, ESRD Clinical Performance Measures Project 2002 Annual Report on, S2:39–48
- anatomic findings in, 1082–1096
- carotid atherosclerosis, factors associated with, 355–361
- complications, peritoneal-mediastinal leakage, 2:E7
- core curriculum, 1082–1096
- culture-negative peritonitis, clinical course in, 567–574
- in diagnostic and interventional nephrology program, 229–233
- gastrointestinal and pancreatic function in, 787–796
- hypertension treatment in, 1260–1269
- long-term
 - amino acid dialysate in, 173–183
 - gabapentin-induced hypoglycemia in, 6:E24
 - for mucormycosis peritonitis, liposomal amphotericin B for, 3:E13
 - peritonitis, depression and, 350–354
- outcome, impact of referral in ESRD, 474–485
- peritoneoscopic catheter insertion, bowel perforation from, 1270–1274
- ultrafiltration volume, measurement by segmental bioimpedance analysis, 167–172

Peritoneal equilibrium test, in nephrology core curriculum, 1082–1096

Peritoneal-mediastinal leakage, as peritoneal dialysis complication, 2:E7

Peritoneal membrane

- abnormalities, malnutrition and, 787–796
- anatomy of, 1082–1096
- function in uremia, ENOS gene polymorphisms and, 781–786

Peritoneoscopy, for PD catheter insertion, bowel perforation from, 1270–1274

Peritonitis

- culture-negative, clinical course in peritoneal dialysis, 567–574
- in long-term peritoneal dialysis, depression and, 350–354
- mucormycosis, long-term PD and liposomal amphotericin B for, 3:E13

P-glycoprotein, hepatic drug metabolism in kidney disease and, 906–925

Pharmacokinetics

- of drugs in kidney disease, 906–925
- of levofloxacin in ESRD, 342–349
- single-dose ofloxacin in CVVH, 310–314

Phosphate, quotidian hemodialysis and, S1:24–29

Phosphate binders

- in chronic kidney disease, K/DOQI Clinical Practice Guidelines, S3:70–77
- lanthanum carbonate, safety/efficacy of, 96–107

Phosphorus, serum

- assessment in chronic kidney disease, S3:62–63
- lanthanum carbonate effects on, 96–107
- metabolism evaluation, S3:52–57

PKD (polycystic kidney disease), autosomal recessive and dominant, 1305–1317

Plasma cell dyscrasia, with focal segmental glomerulosclerosis, 1097–1101

Plasmapheresis, for diffuse alveolar hemorrhage in small-vessel vasculitis, 1149–1153

Platelet aggregation test, vs. in vitro closure time test for hemostasis assessment in HD patients, 746–751

Platelet glycoprotein receptor inhibitors, for acute coronary syndromes in renal patients, 446–455

Pneumonia, severe acute respiratory syndrome in hemodialysis patient, 1069–1074

Podocin, in congenital nephrotic syndrome, 1318–1323

Podocytes

- in congenital nephrotic syndrome, 1318–1323
- crystals in, 605–611
- vascular endothelial growth factor expression, in MGN, 1139–1148

Polyarteritis nodosa, subarachnoid hemorrhages in, 582–585

Polycystic kidney disease (PKD), autosomal recessive and dominant, 1305–1317

Polymerase chain reaction (PCR), evaluation of HBV- and HCV-infected renal allografts, 193–201

Polymorphisms

- C-106T of *AKR1B1*, in diabetic nephropathy, 943–951
- matrix metalloproteinase 9 gene, in ESRD, 133–142

Polyoma BK virus-associated interstitial nephritis, allograft loss, retransplantation after, 821–825

Polysulfone capillary hemofilter, single-dose ofloxacin pharmacokinetics and, 310–314

Positron emission tomography, of renal malacoplakia, 3:E17

Poverty, receipt of renal replacement therapy and, 249–255

Predialysis psychoeducational intervention, time to dialysis and, 693–703

Prednisolone with mycophenolate mofetil, for steroid-dependent nephrotic syndrome, 1114–1120

Prednisone, with LDL apheresis, for steroid-resistant focal segmental glomerulosclerosis, 1121–1130

Preeclampsia, hypertensive pregnancy and, 982–989

Preemptive renal transplantation

- residual renal function effects on graft and patient survival rates, 1275–1282
- vs. nonpreemptive renal transplantation, 1050–1057

Preexisting crescentic glomerulonephritis, in renal allograft, 5:E23

Pregnancy, hypertensive, cardiovascular disease and thromboembolic events associated with, 982–989

Prognosis

- cardiac markers in ESRD, 513–523
- in light chain deposition disease with renal involvement, 1154–1163
- of MPGN type I renal dysfunction, α -smooth muscle actin and, 1131–1138

Program to Improve Care in Acute Renal Disease (PICARD), reasons for nonenrollment in, 507–512

Progression

- of atherosclerotic renal artery stenosis, medical management of, 851–857
- of IgA nephropathy, nuclear factor κ -B and, 76–86
- of renal insufficiency in type 2 diabetes, 936–942

Protein-energy malnutrition
erythropoietin hyporesponsiveness in maintenance HD and, 761–773
with inflammation in dialysis, 864–881

Protein kinase C β inhibition, for diabetic nephropathy with vascular complications, 456–465

Protein-losing enteropathy, in peritoneal dialysis patients, 787–796

Protein turnover, in ESRD hemodialysis patients, 1212–1220

Proteinuria
in crescentic glomerulonephritis, doxycycline effects on, 376–380
in nondiabetic nephropathy, effect of verapamil vs. amlopipidine for, 67–75
position statement of NKF and NIDDK, 617–622
prognosis for LCDD with renal involvement, 1154–1163
progression of renal insufficiency in type 2 diabetes mellitus, 936–942
urinary NAG excretion in type 2 diabetes, pentoxifylline effects on, 264–270
VEGF excretion in idiopathic MGN, 1139–1148

Proteolysis, in ESRD hemodialysis patients, 1212–1220

Psoriasis vulgaris, with protein glomerulopathy and apolipoprotein E3/3, 3:E14

Psychosocial factors, quality of life in ESRD and, 713–721

PTH. *See Parathyroid hormone*

Pyuria, targeted kidney disease screening and, 22–35

Quality improvement, clinical performance measures based on K/DOQI Clinical Practice Guidelines, 806–812

Quality of life
after kidney and pancreas transplantation, 431–445
in ESRD, S5:151–160
conversion from conventional to daily HD, 1020–1035
symptoms, spiritual beliefs, psychosocial factors and ethnicity, 713–721
pain in hemodialysis and, 1239–1247
on quotidian hemodialysis, S1:36–41

Quotidian hemodialysis
adequacy of, S1:42–48
anemia management, S1:18–23
calcium and phosphate balance in, S1:24–29
conventional vs. home, cost comparison of, S1:49–55
equipment and water treatment considerations, S1:66–70
nursing issues, S1:56–60
nutritional status and, S1:30–35
patient quality of life, S1:36–41
volume control and blood pressure management in, S1:13–17

Race
chronic kidney disease risk and, S4:34–S4:41
quality of life in ESRD and, 713–721

Randomized controlled trials. *See specific randomized controlled trials*
of ARF, reasons for nonenrollment in, 507–512
Cochrane Renal Group report on, 837–841

Recombinant human erythropoietin (rHuEPO)
hemodialysis membrane composition effect on erythrocyte response, 551–560

hyporesponsiveness in maintenance HD, malnutrition-inflammation complex syndrome and, 761–773
Recurrence of ANCA-positive glomerulonephritis, after kidney transplantation, 4:E18

Reference values, for microalbuminuria testing, 245–248

Referrals
impact on outcomes in ESRD, 474–485
late, access to kidney transplantation and, 1043–1049

Regeneration, stem cell therapy for renal disease, 891–905

Rehabilitation, ESRD, S5:151–160

Religion, quality of life in ESRD and, 713–721

Renal artery stenosis
atherosclerosis, medical management of, 851–857, 858–863
stent placement, predictive value of renal insufficiency in, 926–935

Renal biopsy
of congenital nephrotic syndrome, 1318–1323
evaluation of HBV- and HCV-infected renal allografts, 193–201
nephrology core curriculum, 826–836
non-minimal change nephrotic syndrome in children, 1107–1113
percutaneous, for lymphoma diagnosis, 960–971
preexisting crescentic glomerulonephritis in renal allograft, 5:E23
ultrasound guided in diagnostic and interventional nephrology program, 229–233

Renal cell carcinoma, multicentric papillary, in renal allograft, 381–384

Renal failure/insufficiency. *See also Acute renal failure; Chronic kidney disease*
with acute coronary syndromes, antithrombotic agents for, 446–455
circulating AGEs, dietary glycotoxins and, 532–538
clinical course of culture-negative peritonitis complicating PD, 567–574
in light chain deposition disease, 1154–1163
predictive value of renal artery stent placement, 926–935
rapidly progressive, with pancreatic insufficiency, 842–845
stem cell therapy for, 891–905
in vitro closure time test for hemostasis assessment in, 746–751

Renal hyperparathyroidism, percutaneous ethanol injection therapy effectiveness in HD patients, 739–745

Renal lymphoma, diagnosed by percutaneous kidney biopsy, 960–971

Renal malacoplakia, positron emission tomography of, 3:E17

Renal osteodystrophy, in HD patients, serum leptin in, 1036–1042

Renal replacement therapy. *See also specific renal replacement therapies*
in Finland, cost analysis of, 1228–1238
predialysis psychoeducational interventions, time to dialysis and, 693–703
single-dose ofloxacin pharmacokinetics in, 310–314
for type 1 diabetes, incidence of ESRD and survival after, 117–124

Renal stem cells, for kidney disease, 891–905

Renal transplantation. *See* Kidney transplantation
Renal tubular dysfunction, in β -thalassemia minor, 1164–1168
Renal tubular regeneration, by bone marrow-derived cells after BMT, 5:E20
Renal ultrasonography, for diagnostic and interventional nephrology program, 229–233
Renovascular hypertension, atherosclerotic renal artery stenosis and, 858–863
Residual renal function, graft and patient survival rates in preemptive renal transplant patients, 1275–1282
Resistin, insulin resistance in renal disease and, 62–66
Restenosis, access blood flow monitoring methods and, 539–545
Retinal abnormalities, in mesangiocapillary glomerulonephritis type II, 2:E3
Retrograde pyelography, acute renal failure after, 2:E6
Revascularization, of atherosclerotic renal artery stenosis, 851–857, 858–863
Reverse epidemiology, malnutrition-inflammation complex syndrome in dialysis and, 864–881
rHuEPO. *See* Recombinant human erythropoietin
Ribavirin
for hepatitis C virus-related renal disease, 631–657
long-term therapy for HCV-positive renal transplant patients, 184–192
Risk adjustment, adapting Charlson Comorbidity Index for ESRD, 125–132
Risk factors
for aortic atherosclerosis, in chronic renal failure, 277–285
for chronic kidney disease, KEEP program participants and, S4:34–S4:41
Rosiglitazone, glucose metabolism in nondiabetic uremic patients on CAPD and, 774–780
Ruboxostaurin, for diabetic nephropathy with vascular complications, 456–465
Salivary secretion, in end-stage renal disease, 722–728
Sacroileitis, adult-onset tubulointerstitial nephritis and uveitis and, 3:E11
SARS. *See* Severe acute respiratory syndrome
Saxon's test, in long-term dialysis patient with ESRD, 722–728
Screening, targeted for early kidney disease evaluation, 22–35
Segmental bioimpedance analysis, of ultrafiltration volume in peritoneal dialysis, 167–172
Selection bias, reasons for nonenrollment in ARF cohort study, 507–512
Seroconversion of HBV, stage of chronic kidney disease and, 1184–1192
Sevelamer, and calcium acetate, bioavailability of ciprofloxacin and, 1253–1259
Severe acute respiratory syndrome (SARS)
in dialysis patients, clinical presentation and outcome of, 1075–1081
in hemodialysis patient, 1069–1074
Severity of illness, adapting Charlson Comorbidity Index for ESRD, 125–132
Shirmer's test, in long-term dialysis patient with ESRD, 722–728
Sickle cell disease, multiorgan failure during sickle cell crisis in sickle/ β -thalassemia, E4
Signal transduction inhibition, for diabetic nephropathy with vascular complications, 456–465
Sirolimus-induced thrombotic microangiopathy, in renal transplant recipient, 202–206, 1058–1068
Sjogren's syndrome, with Gitelman's syndrome presenting with muscular paralysis, 586–590
Skin bleeding time, *vs.* in vitro closure time test for hemostasis assessment in HD patients, 746–751
SLE. *See* Systemic lupus erythematosus
Small bowel transplant, rejection-related diarrhea, hypochloremic metabolic alkalosis from, 1283–1286
Small-vessel vasculitis, diffuse alveolar hemorrhage, plasmapheresis for, 1149–1153
Smoking, KEEP program patients, S4:16–27
 α -Smooth muscle actin, MPGN type I renal dysfunction prognosis and, 1131–1138
Socioeconomic status
chronic kidney disease incidence and outcomes and, 677–684
dysregulation of immune balance resulting in glomerulonephritis, 575–581
receipt of renal replacement therapy and, 249–255
Sodium-chloride cotransporter, Gitelman's syndrome with Sjogren's syndrome, 586–590
Sodium fractional excretion, renal tubular dysfunction in β -thalassemia minor, 1164–1168
Southwestern histochemistry, detection of nuclear factor κ -B in IgA nephropathy, 76–86
Specimen handling, for microalbuminuria testing, 245–248
Spirituality, quality of life in ESRD and, 713–721
Starvation, severe acidosis caused by, 5:E22
STAT6 gene polymorphisms, in children with minimal change nephrotic syndrome, 271–276
Steal syndrome, transposed basilic vein arteriovenous fistula and, 151–157
Stem cell therapy
autologous transplantation, for LCDD with renal involvement, 1154–1163
for renal disease, 891–905
Stenosis
detection in AVFs, ultrasound dilution blood flow rate for, 331–341
renal artery
atherosclerosis, medical management of, 851–857, 858–863
stent placement, predictive value of renal insufficiency in, 926–935
restenosis, access blood flow monitoring methods and, 539–545
in vivo validation of glucose pump test for access flow, 752–760
Steroid resistance
in focal segmental glomerulosclerosis, prednisone and LDL apheresis for, 1121–1130
in minimal change nephrotic syndrome, tacrolimus for, 5:E21
Stone disease, Tamm-Horsfall glycoprotein and, 658–676

Stress
 oxidative
 during hemodialysis, ascorbic acid effects on, 158–166
 in maintenance HD patients with hypoalbuminemia, 286–294
 severe acidosis caused by, 5:E22

Stroke, hypertensive pregnancy and, 982–989

Strontium absorption test, intestinal calcium absorption in hypercalcic stone-forming women and, 1177–1183

Subarachnoid hemorrhages, in vasculitis, 582–585

Surgical technique, in predicting successful AVF maturation, 1000–1012

Surveillance, access, in vivo validation of glucose pump test for access flow, 752–760

Survival
 in ESRD, Charlson Comorbidity Index prediction of, 125–132
 light chain deposition disease with renal involvement, 1154–1163
 residual renal function in preemptive kidney transplantation and, 1275–1282

Symptoms, quality of life in ESRD and, 713–721

Systemic lupus erythematosus
 de novo after cadaveric renal transplantation, 3:E15
 hemodialysis patient with ESRD and SARS, 1069–1074

Tacrolimus
 in steroid- and cyclophosphamide-resistant MCNS, 5:E21
 thrombotic microangiopathy after renal transplantation and, 1058–1068

Tamm-Horsfall glycoprotein
 biology and clinical relevance, 658–676
 uromodulin gene mutations, renal manifestations of, E8

Terminal illness, analgesia in end-stage renal disease, 217–228

Thalassemia, multiorgan failure during sickle cell crisis in sickle/ β -thalassemia, E4

β -Thalassemia minor, renal tubular dysfunction in, 1164–1168

T helper cell subsets, hygiene and socioeconomic dysregulation, glomerulonephritis development and, 575–581

Thiazide, for Gitelman's syndrome with Sjogren's syndrome, 586–590

Thin basement membrane disease, nephrology core curriculum, 1305–1317

Thromboembolism, hypertensive pregnancy and, 982–989

Thrombolytics, for acute coronary syndromes in renal patients, 446–455

Thrombosis, prediction in AVFs, ultrasound dilution blood flow rate for, 331–341

Thrombotic microangioplasty, after renal transplantation, 1058–1068

Thrombotic thrombocytopenic purpura, thrombotic microangiopathy after renal transplantation and, 1058–1068

Time to dialysis, predialysis psychoeducational intervention and coping styles, 693–703

Time trade-off, quality of life on quotidian hemodialysis, S1:36–41

Tonsillar lymphocytes, IgA1, O-glycan structure in IgA nephropathy, 486–496

Training, nurse, in quotidian hemodialysis, S1:56–60

Tramadol, in end-stage renal disease, 217–228

Trandolapril, with verapamil vs. amlodipine in nondiabetic nephropathy, 67–75

Transesophageal echocardiography, of aortic atherosclerosis in CRF, 277–285

Transposed basilic vein arteriovenous fistula, vascular access outcomes, 151–157

Triple-lumen catheters, vs. dual-lumen catheters for hemodialysis and apheresis, 315–324

Tropins, prognostic value in ESRD, 513–523

Tuberous sclerosis complex, nephrology core curriculum, 1305–1317

Tubulointerstitial injury, urinary NAG excretion in type 2 diabetes, pentoxifylline effects on, 264–270

Tubulointerstitial nephritis
 Gitelman's syndrome with Sjogren's syndrome, 586–590
 Tamm-Horsfall glycoprotein and, 658–676
 and uveitis, associated with sacroileitis and EBV infection, 3:E11

Tumor necrosis factor- α
 effect of malnutrition-inflammation complex on EPO hypersensitivity in maintenance HD, 761–773

in ESRD hemodialysis patients, 1212–1220

in peritoneal dialysis patients, 787–796

urinary albumin excretion in type 2 diabetes mellitus and, 53–61

Ubiquitin, in ESRD hemodialysis patients, 1212–1220

Ubiquitin-proteasome pathway, hemodialysis effects on, 1212–1220

Ultrafiltration volume measurement, by segmental bioimpedance analysis, 167–172

Ultrasonography
 for diagnostic and interventional nephrology program, 229–233
 dilution method
 access blood flow in AVFs, 331–341
 vs. color Doppler ultrasound or fistulography, 539–545

United States Renal Data System (USRDS)
 analytic methods, S5:182–213
 2003 annual data report, S5:4–224
 chronic kidney disease, S5:37–46
 ESRD
 cardiovascular special studies, S5:141–150
 clinical indicators and preventive care, S5:87–102
 economic costs, S5:161–172
 incidence and prevalence, S5:47–60
 international comparisons, S5:173–181
 outcomes, S5:103–114
 patient characteristics, S5:61–74
 pediatric, S5:129–140
 program overview, S5:13–24
 rehabilitation and quality of life, S5:151–160
 transplantation, S5:115–128
 treatment modalities, S5:75–86

Healthy People 2010, S5:25–36

services, S5:214–223

thrombotic microangiopathy after renal transplantation and, 1058–1068

UNOS Point System, for cadaver kidney allocation, 882–890

URAT1 gene, exercise-induced ARF with familial renal hypouricemia, 1287–1292

Urea filtration rate/volume, quotidian hemodialysis and, S1:42–48

Urea kinetics, quotidian hemodialysis and, S1:42–48

Uremia

- dialysis membrane composition effect on erythrocyte response, 551–560
- nondiabetic, rosiglitazone effect on insulin resistance in CAPD, 774–780
- pamidronate for in postmenopausal HD patients with secondary hyperparathyroidism, 1221–1227
- resistin blood levels in, 62–66

Urinary biomarker, for tubular injury in ARF, 497–506

Urinary calculi, in cystic fibrosis, 1–11

Urinary proteins, Tamm-Horsfall glycoprotein, 658–676

Urine volume, nephrolithiasis in cystic fibrosis and, 1–11

Urolithiasis

- in cystic fibrosis, 1–11
- Tamm-Horsfall glycoprotein and, 658–676

Uromodulin

- gene mutations, renal manifestations of, 2:E8
- Tamm-Horsfall glycoprotein and, 658–676

USRDS. *See United States Renal Data System*

Vascular access. *See also specific vascular access methods*

- blood flow monitoring
 - by ultrasound dilution blood method, for AVFs, 331–341
 - ultrasound dilution vs. color Doppler ultrasound or fistulography, 539–545
 - in vivo validation of glucose pump test for, 752–760
 - conversion from conventional hemodialysis to daily hemodialysis for ESRD patients, 1020–1035
 - in London Daily/Nocturnal Hemodialysis Study, S1:5–12
 - outcome, transposed basilic vein arteriovenous fistula and, 151–157
 - patency, transposed basilic vein arteriovenous fistula and, 151–157
 - predictors of successful AVF maturation, 1000–1012
 - in quotidian hemodialysis, S1:56–60
- recirculation, ultrasound dilution blood method for AVFs, 331–341
- Vascular calcification, in long-term HD, serum osteoprotegerin and, 303–309
- Vascular disease, progression of renal insufficiency in type 2 diabetes mellitus, 936–942
- Vascular endothelial growth factor, urinary excretion, MGN clinical course and, 1139–1148
- Vasculitis

 - with glomerulonephritis, effects of doxycycline on, 366–380
 - subarachnoid hemorrhages in, 582–585

- Verapamil, with trandolapril, proteinuria in nondiabetic nephropathy and, 67–75
- Viral replication, HBV and HCV in renal allograft, evaluation of, 193–201
- Visual impairment, in mesangiocapillary glomerulonephritis type II, 2:E3
- Vitamin C, effect on oxidative stress parameters in HD, 158–166
- Vitamin D

 - insufficiency/deficiency, treatment of, S3:84–89
 - metabolic alterations in CKD, S3:29–44
 - therapy
 - for CKD patients, S3:89–92
 - for dialysis patients, S3:92–98

Water treatment, for quotidian hemodialysis, S1:66–70

White blood cell count, chronic kidney disease and, 256–263

Women

- chronic kidney disease risk and, S4:34–S4:41
- hypercalcicuric stone-forming, intestinal calcium absorption and BMD in, 1177–1183
- postmenopausal, pamidronate for secondary hyperparathyroidism in, 1221–1227
- quality of life in ESRD and, 713–721
- thrombotic microangiopathy after renal transplantation and, 1058–1068

Xerophthalmia, in end-stage renal disease, 722–728

Xerostomia, in end-stage renal disease, 722–728

Zinc excretion, renal tubular dysfunction in β -thalassemia minor, 1164–1168